

**THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF ILLINOIS**

*In re Tecfidera Antitrust Litigation*

This Document Relate to:  
All Actions

No. 1:24-cv-07387

Hon. Franklin U. Valderrama

DEMAND FOR JURY TRIAL

**CONSOLIDATED AMENDED CLASS ACTION COMPLAINT**

## **TABLE OF CONTENTS**

I.	NATURE OF THE ACTION .....	1
II.	PARTIES AND BIOGEN’S CO-CONSPIRATORS .....	7
A.	Plaintiffs .....	7
B.	Defendant .....	11
C.	Co-Conspirators .....	11
III.	JURISDICTION AND VENUE .....	15
IV.	THE IMPORTANCE OF GENERIC DRUGS .....	16
A.	The High Price of Branded Drugs .....	16
B.	The Regulatory Structure that Promotes Generic Drugs .....	18
C.	The Competitive Effects of AB-rated Generic Competition .....	20
V.	THE PROMISE AND PERILS OF PBMS .....	21
A.	The Promise .....	21
B.	The Perils .....	24
VI.	BRAND MANUFACTURERS’ ANTICOMPETITIVE TACTICS .....	30
A.	Market Switches .....	30
B.	Kickbacks to PBMs .....	32
VII.	BIOGEN’S DEVELOPMENT AND SALES OF TECFIDERA AND VUMERITY .....	36
A.	Multiple Sclerosis Is a Chronic Disease for Nearly One Million Americans .....	36
B.	Biogen Made Billions Selling Tecfidera for More Than \$90,000 Per Patient Per Year .....	36
VIII.	BIOGEN’S PLAN TO DEFEAT GENERIC COMPETITION .....	38
A.	Biogen Planned to Defeat Generic Competition with an “Evergreen” Strategy. .	38
B.	Biogen Planned, but Failed, to Switch the Market to Vumerity Before Generic Tecfidera Entered the Market. ....	41

1.	Biogen Readied Vumerity If It Lost the Patent Litigation.....	41
2.	Biogen’s Sole Motive Was to Impair Generic Tecfidera.....	43
3.	Biogen Botched the Timing of the Market Switch. ....	44
IX.	BIOGEN PAID THE PBMS TO IMPAIR COMPETITION FROM GENERIC TECFIDERA.....	48
A.	Biogen Paid Increased Rebates and Fees to PBMs for Impairing Generic Tecfidera. ....	49
B.	Biogen’s Scheme Caused PBMs to Designate Generic Tecfidera a Specialty Drug. ....	52
X.	BIOGEN’S CORRUPT AGREEMENTS WITH THE PBMS SUPPRESSED GENERIC COMPETITION. ....	54
A.	OptumRx’s Formularies.....	54
B.	CVS Caremark’s Formularies.....	56
C.	Express Scripts’ Formularies .....	57
D.	The Cumulative Numbers .....	58
E.	The Resulting Massive Increases in Biogen’s Branded Sales. ....	60
XI.	THE SCHEME’S ANTICOMPETITIVE EFFECTS .....	65
XII.	CLASS ACTION ALLEGATIONS .....	66
XIII.	INTERSTATE AND INTRASTATE COMMERCE .....	69
XIV.	MARKET POWER AND MARKET DEFINITION .....	70
XV.	MARKET EFFECTS AND DAMAGES TO THE CLASS .....	72
XVI.	ANTITRUST IMPACT .....	74
XVII.	COMPLIANCE WITH NOTICE AND DEMAND REQUIREMENTS .....	75
XVIII.	CLAIMS FOR RELIEF .....	76
XIX.	DEMAND FOR JUDGMENT.....	93
XX.	JURY DEMAND .....	94

Plaintiffs Local No. 1 Health Fund, Mayor and City Council of Baltimore, Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund, New York State Teamsters Council Health and Hospital Fund, and UFCW Local 1500 Welfare Fund (together, "Plaintiffs"), are health-benefit plans, or the sponsors of such plans, that provide healthcare benefits to their members. Plaintiffs, on behalf of themselves and all others similarly situated, based upon personal knowledge, the investigation of counsel, and upon information and belief, file this Consolidated Amended Class Action Complaint ("Complaint") and allege as follows against defendant Biogen Inc. ("Biogen"):

### **I. NATURE OF THE ACTION**

1. This civil antitrust action seeks damages and other relief arising out of defendant Biogen Inc.'s unlawful scheme to impair competition from generic versions of its brand-name prescription drug Tecfidera. Tecfidera is used to treat multiple sclerosis ("MS").

2. The Food and Drug Administration ("FDA") approved Tecfidera in 2013, and it quickly reached blockbuster status, achieving \$3.5 billion in U.S. sales by 2015 and remaining in the range of \$3.3 to \$3.8 billion annually through 2020.

3. These sales reflected Tecfidera's extremely high sales price, which rose to nearly \$90,000 per patient per year. Biogen's manufacturing costs were less than \$300 per patient per year—it sold Tecfidera at 300 times its costs. Biogen was able to reap these monopoly profits because it had a patent on Tecfidera.

4. But that patent was very weak. Beginning in 2017—as soon as legally permissible—numerous generic-drug manufacturers began challenging the validity of the Tecfidera patent. Biogen knew that once it lost those patent lawsuits its Tecfidera sales and profits would fall off the "patent cliff." Generic versions would quickly take 90% or more of the

unit sales and would be sold at a small fraction of Biogen's price. This competition would save billions of dollars for Plaintiffs and other purchasers of Tecfidera.

5. To forestall this competition and the consequent loss of its sales, Biogen crafted a market-switch strategy. Biogen developed a "next generation" version of Tecfidera, called Vumerity. Vumerity and Tecfidera create the same active drug substance—monomethyl fumarate—in the body. They each deliver the same bioequivalent exposure to monomethyl fumarate and therefore have the same effectiveness and safety profile. In fact, Biogen got expedited FDA approval of Vumerity by proving that it was bioequivalent to Tecfidera, i.e., that its active ingredient is present in the patient's blood to the same extent and for the same amount of time.

6. Vumerity was different from Tecfidera not in a medically important way, but in an *economically* important way. When filling a prescription written for Vumerity, pharmacists could not automatically substitute generic Tecfidera. So Biogen's plan was to orchestrate a market switch—to get doctors to switch their prescribing from Tecfidera to Vumerity before the generic versions of Tecfidera were available in the marketplace. Biogen would tell doctors and patients that Vumerity was "new and improved" even though in fact it had no medically significant advantages over Tecfidera. If doctors wrote prescriptions for Vumerity rather than Tecfidera, pharmacists could not dispense generic Tecfidera for those prescriptions.

7. Timing was essential to Biogen's scheme. Biogen would need to accomplish the market switch before generic Tecfidera became available. It is well known in the industry that a switch to a follow-on product like Vumerity—one with no important medical improvements—would succeed only if the switch occurred before generic versions of the original product became available.

8. Biogen ran into three problems on the timing of its planned market switch. Biogen's launch of Vumerity was complicated by the onset of the coronavirus disease 2019 ("COVID-19") pandemic, which prevented Biogen's sales force from marketing Vumerity to doctors in-person. And Biogen had planned to get more time to make the market switch by settling the Tecfidera patent lawsuits with an agreement by the generic challengers to delay their entry into the market. That plan went awry because Biogen's patent was so weak that the generic manufacturers refused to settle on those terms. Then when the courts hearing the patent cases ruled that the Tecfidera patent was invalid, the generic manufacturers entered the market immediately, without waiting to see if the invalidity ruling would be upheld on appeal (as it eventually was). This cut 18 months off the time that Biogen thought it would have to make the market switch from Tecfidera to Vumerity.

9. The cumulative effect of Biogen's timing problems was stark. Instead of having converted nearly 100% of Tecfidera sales to Vumerity before the Tecfidera generics entered the market, Biogen had converted about 1% of them.

10. So Biogen resorted to using unlawful, anticompetitive agreements to foreclose generic companies from a substantial share of the market and block them from the most cost-efficient means of competing with Biogen, while it scrambled to switch the market. Biogen entered into unlawful restraints of trade with each of the nation's three largest pharmacy benefit managers—Caremark Rx, LLC, OptumRx, Inc., and Express Scripts, Inc. Collectively, these three Pharmacy Benefit Managers ("PBMs") control the pharmacy benefits for 80% of Americans. Pursuant to these exclusionary agreements, Biogen paid the PBMs to manipulate the placement of generic Tecfidera on their formularies—the lists that identify which drugs are covered and establish the applicable patient copayments and coinsurance.

11. Biogen paid each of the three PBMs (and others) to refrain from advantaging generic Tecfidera over branded Tecfidera and Vumerity on their formularies, thereby foreclosing them from a substantial portion of the market. Biogen labeled these payments as “rebates” or “fees.” In reality they were kickbacks to the PBMs for helping to insulate Tecfidera and Vumerity from lower-priced generic competition.

12. While the PBMs passed some of the rebates (none of the fees) on to some of their customers, the rebates were not legitimate and honest ways for Biogen to compete with generic Tecfidera on price. Seven months after entering the market, generic Tecfidera was selling for greater than a 90% discount off the list price of branded Tecfidera. In contrast, Biogen’s average rebates and fees on branded Tecfidera were less than 19% off the list price. Biogen’s rebates and fees were payments *to the PBMs* in exchange for excluding the generics, not price reductions to the health plans that, even if fully passed on to them, would have produced savings anywhere near what the generics offered.

13. These bought-and-paid-for manipulations substantially muted the competition from generic Tecfidera. That period of impaired competition, in turn, gave Biogen the time it needed to switch a large portion of the market from Tecfidera to Vumerity. That market switch significantly and permanently impaired generic competition, and the harms from it continue today.

14. Piling injury upon injury, Biogen’s requirement that the PBMs not advantage generic Tecfidera on the formularies caused some of them to designate generic Tecfidera as a “specialty drug.” But nothing about generic Tecfidera required special handling—it is a shelf-stable pharmaceutical dispensed as a pill. Nor did it carry a high acquisition cost which

sometimes results in a product being designated a “specialty drug.” This was not a legitimate designation for generic Tecfidera.

15. The purpose and effect of Biogen’s causing that designation was to require insured patients to incur a very high copayment or coinsurance for generic Tecfidera, muting their incentive to demand or accept the generic. Another purpose and effect was to require that the falsely designated generic be dispensed only through a small number of “specialty pharmacies,” shielding those pharmacies from price competition from all other pharmacies. Notably, Biogen’s co-conspirator PBMs owned specialty pharmacies.

16. Biogen knew and intended that causing generic Tecfidera to be distributed through this small set of specialty pharmacies would substantially depress the sales of generic Tecfidera. It kept generic Tecfidera’s price to health plans and other purchasers astronomically high. The PBM-affiliated specialty pharmacies bought generic Tecfidera from the manufacturers for as little as \$180 for a 30-day supply; they sold it to the health plans and their insureds for as much as \$3,857 for a 30-day supply. That is more than a 2,000% markup.

17. Biogen’s conduct had the intended effect. With unimpaired generic competition, within 10 months of generic availability pharmacies would have been dispensing about 2.2 million units of generic Tecfidera every month; instead they were dispensing about a third of that amount. Correspondingly, pharmacies would have been dispensing fewer than 300,000 units of branded Tecfidera and Vumerity (combined) every month; instead they were dispensing more than five times that amount. Even today—four years after generic entry—Biogen’s unlawful conduct has suppressed generic Tecfidera sales far below the competitive level, while artificially inflating the sales of high-priced Tecfidera/Vumerity. For the remaining percentage of Tecfidera prescriptions filled with the generic, despite Biogen’s efforts, health plans and other purchasers



paid substantially more than they otherwise would have but for the PBMs' improper designation of generic Tecfidera as a specialty drug.

18. When making the payoffs to the PBMs, Biogen knew that Plaintiffs and other health plans hired the PBMs to negotiate with Biogen and other drug manufacturers on their behalf. Biogen knew that health plans trusted the PBMs to make formulary placement decisions to help them reduce prescription drug costs. Biogen paid the PBMs to instead impair the generic competition that it was the PBMs' proper, lawful role and obligation to promote.

19. Biogen also knew that each of the three PBMs had recently established a separate, affiliated "rebate aggregator"—an entity that negotiates contracts, including for fees and rebates, with drug manufacturers. When making the payoffs at issue here, Biogen knew that one of the functions of the PBMs' affiliated rebate aggregators was to hide the rebates and fees from the PBMs' health-plan clients. A former OptumRx executive who helped establish its affiliated rebate aggregator explained that "[t]he intention of the [rebate aggregator] is to create a fee structure that can be retained and not passed on to a client."

20. All of this occurred at the expense of MS patients and health plans such as Plaintiffs, which were forced to continue paying supracompetitive prices for Vumerity, Tecfidera, and its generic equivalents. Biogen denied to purchasers the massive cost savings that would and should have resulted from unimpaired generic competition.

21. These supracompetitive prices place a notable financial strain on health plans, because they directly shoulder the burden of high-cost prescription drugs. Smaller businesses feel this strain most acutely; the high cost of even a single specialty medication can represent a significant proportion of the overall health-benefit costs.

22. Together with its PBM Co-Conspirators, Biogen has unlawfully (1) restrained, suppressed, and eliminated competition in the market for Vumerity, Tecfidera, and their generic equivalents; (2) maintained monopoly and supracompetitive prices for those drug products; and (3) prevented Plaintiffs from purchasing the drugs in a competitive market, robbing them of billions of dollars in the aggregate.

## **II. PARTIES AND BIOGEN’S CO-CONSPIRATORS**

### **A. Plaintiffs**

23. Plaintiff Local No. 1 Health Fund (“Local 1 Health Fund”) is a multi-employer welfare plan whose stated purpose is to provide health benefits to eligible members and dependents. Local 1 Health Fund is maintained and administered in accordance with and pursuant to the provisions of § 302(c)(5) of the National Labor Relations Act. Local 1 Health Fund’s principal place of business is located at 1431 Opus Place, Suite 350, Downers Grove, Illinois. It is a self-insured health and welfare benefit plan, and it purchases, pays and/or provides reimbursement for some or all of the purchase price of prescription drugs, including Vumerity, Tecfidera, or its generic equivalents.

24. During the Class Period, Local 1 Health Fund and other Class members purchased substantial amounts of Tecfidera, generic Tecfidera, and/or Vumerity in, among other jurisdictions, Illinois, other than for resale. Local 1 Health Fund and other Class members bought these products directly from Biogen or its Co-Conspirator specialty pharmacies (such as Accredo Health Group, Inc. (“Accredo”) and CVS Specialty Pharmacy) and/or indirectly from others. Local 1 Health Fund and other Class members paid more for Vumerity, Tecfidera, or its generic equivalents than they would have absent Biogen’s unlawful anticompetitive conduct and were injured as a result. If generic alternatives to Tecfidera had been competitively available during the Class Period, Local 1 Health Fund and the other Class members would have purchased more

of the less expensive generic alternatives rather than branded Tecfidera or Vumerity, and/or would have paid less for generic Tecfidera.

25. Plaintiff, the Mayor and City Council of Baltimore (“City of Baltimore”) is a municipality located in Baltimore, Maryland. City of Baltimore provides health benefits to eligible employees, retirees, and their beneficiaries. City of Baltimore provides self-insured prescription drug coverage, and it purchases, pays and/or provides reimbursement for some or all of the purchase price of prescription drugs, including Vumerity, Tecfidera, or its generic equivalents.

26. During the Class Period, City of Baltimore purchased substantial amounts of Tecfidera, generic Tecfidera, and/or Vumerity in, among other jurisdictions, Florida and Maryland, for the personal use of its members and beneficiaries, other than for resale. City of Baltimore and other Class members bought these products directly from Biogen or its Co-Conspirator specialty pharmacies (such as CVS Specialty Pharmacy) and/or indirectly from others. City of Baltimore and other Class members paid more for Vumerity, Tecfidera, or its generic equivalents than they would have absent Biogen’s unlawful anticompetitive conduct and were injured as a result. If generic alternatives to Tecfidera had been competitively available during the Class Period, City of Baltimore and the other Class members would have purchased more of the less expensive generic alternatives rather than branded Tecfidera or Vumerity, and/or would have paid less for generic Tecfidera.

27. Plaintiffs Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees’ Benefit Fund (collectively “Teamsters Local 237”) are two related health and welfare benefit plans headquartered and with a principal place of business in New York, New York. Teamsters Local 237 administer the assets of defined contribution plans formed to provide certain benefits

including prescription drug benefits. Teamsters Local 237 provide health and welfare benefits to active and retired members and participants who reside in numerous locations in the United States. They are self-insured health and welfare benefit plans, and they purchase, pay and/or provide reimbursement for some or all of the purchase price of prescription drugs, including Vumerity, Tecfidera, or its generic equivalents.

28. During the Class Period, Teamsters Local 237 and other Class members purchased substantial amounts of Tecfidera, generic Tecfidera, and/or Vumerity in, among other jurisdictions, New York, North Carolina, Florida, Illinois, Kansas, Indiana, Virginia, Delaware, Pennsylvania, and New Jersey, other than for resale. Teamsters Local 237 and other Class members bought these products directly from Biogen or its Co-Conspirator specialty pharmacies (such as CVS Specialty Pharmacy, Accredo and Aetna Specialty Pharmacy) and/or indirectly from others. Teamsters Local 237 and other Class members paid more for Vumerity, Tecfidera, or its generic equivalents than they would have absent Biogen's unlawful anticompetitive conduct and were injured as a result. If generic alternatives to Tecfidera had been competitively available during the Class Period, Teamsters Local 237 and the other Class Members would have purchased more of the less expensive generic alternatives rather than branded Tecfidera or Vumerity, and/or would have paid less for generic Tecfidera.

29. Plaintiff New York State Teamsters Council Health and Hospital Fund ("NYST") is a self-insured health plan whose purpose is to provide health benefits to eligible members and dependents. NYST's principal place of business is located in Syracuse, New York. During the Class Period, as defined below, NYST purchased, paid, and/or provided reimbursement for some or all of the purchase price of prescription drugs, including Vumerity, Tecfidera, or its generic equivalents.

30. During the Class Period, NYST and other Class members purchased substantial amounts of Tecfidera, generic Tecfidera, and/or Vumerity on behalf of eligible members and dependents in, among other jurisdictions, New York, other than for resale. NYST and other Class members bought these products directly from Biogen or its Co-Conspirator specialty pharmacies (such as Accredo) and/or indirectly from others. NYST and other Class members paid more for Vumerity, Tecfidera, or its generic equivalents than they would have absent Biogen's unlawful anticompetitive conduct and were injured as a result. If generic alternatives to Tecfidera had been competitively available during the Class Period, NYST and the other Class members would have purchased more of the less expensive generic alternatives rather than branded Tecfidera or Vumerity, and/or would have paid less for generic Tecfidera.

31. Plaintiff UFCW Local 1500 Welfare Fund ("Local 1500") is an employee welfare benefits fund with its principal place of business at 425 Merrick Avenue, Westbury, New York. Local 1500 provides nearly 23,000 plan participants with health and welfare benefits and, with over 15,000 members, is the largest grocery union in New York. Local 1500 is a self-insured health and welfare benefit plan, and it purchases, pays and/or provides reimbursement for some or all of the purchase price of prescription drugs, including Vumerity, Tecfidera, or its generic equivalents.

32. During the Class Period, Local 1500 purchased substantial amounts of Tecfidera, generic Tecfidera and/or Vumerity in, among other jurisdictions, New York, for the personal use of its members and beneficiaries, other than for resale. Local 1500 bought these products directly from Biogen or its Co-Conspirator specialty pharmacies (such as Accredo) and/or indirectly from others. Local 1500 and other class members paid more for Vumerity, Tecfidera or its generic equivalents than they would have absent Biogen's unlawful anticompetitive

conduct and were injured as a result. If generic alternatives to Tecfidera had been competitively available during the Class Period, Local 1500 and the other Class members would have purchased more of the less expensive generic alternatives rather than branded Tecfidera or Vumerity, and/or would have paid less for generic Tecfidera.

**B. Defendant**

33. Defendant Biogen is a corporation organized and existing under the laws of the state of Delaware, with its principal place of business at 225 Binney Street, Cambridge, Massachusetts. Biogen is a manufacturer and seller of branded prescription pharmaceuticals, including Tecfidera and Vumerity. It regularly conducts business throughout the United States, including in this judicial district.

34. All of Biogen's actions described in this Complaint are part of, and in furtherance of, the unlawful conduct alleged herein, and were authorized, ordered, and/or done by Biogen's various officers, agents, employees, or other representatives while actively engaged in the management of its affairs (or that of its predecessors-in-interest) within the course and scope of their duties and employment, and/or with the actual, apparent, and/or ostensible authority of Biogen.

**C. Co-Conspirators**

35. Co-Conspirator CVS Health Corporation ("CVS Health") is a corporation organized and existing under the laws of the State of Delaware, with its principal place of business in Woonsocket, Rhode Island. It is a healthcare behemoth that owns and controls, among other entities, a major health insurer, one of the top three PBMs, a specialty pharmacy, a mail-order pharmacy, and more than 9,000 retail pharmacy locations.

36. CVS Health owns, directly or indirectly, CVS Pharmacy, Inc. (“CVS Pharmacy”) and CaremarkPCS Health, L.L.C., which provide pharmacy benefit management services and pharmacy services. Caremark Rx, L.L.C. is a wholly-owned subsidiary of CVS Pharmacy and is the PBM that owns Caremark, LLC, which also provides PBM services. Each of the foregoing CVS Health-affiliated entities has its principal place of business at the same location as CVS Health. CVS Specialty Pharmacy provides specialty pharmacy services. “CVS Specialty Pharmacy” collectively refers to CVS Pharmacy, Caremark Arizona Specialty Pharmacy, L.L.C. (Arizona), Caremark California Specialty Pharmacy, L.L.C. (California), Caremark Florida Specialty Pharmacy, LLC (Florida), Caremark Illinois Specialty Pharmacy, LLC (Illinois), Caremark Kansas Specialty Pharmacy, LLC (Kansas), Caremark Michigan Specialty Pharmacy, LLC (Michigan), Caremark Massachusetts Specialty Pharmacy, L.L.C. (Massachusetts), Caremark New Jersey Specialty Pharmacy, LLC (New Jersey), Caremark North Carolina Specialty Pharmacy, LLC (North Carolina), Caremark Tennessee Specialty Pharmacy, LLC (Tennessee), Caremark Maryland Specialty Pharmacy, LLC (Maryland), and Caremark Minnesota Specialty Pharmacy, LLC (Minnesota).

37. Aetna, Inc. is also a subsidiary of CVS Pharmacy. Aetna, Inc. owns Aetna Health Holdings, LLC which owns Aetna Specialty Pharmacy LLC, a specialty pharmacy services provider. Aetna, Inc., Aetna Holdings, LLC and Aetna Specialty Pharmacy LLC are collectively referred to as “Aetna.”

38. Each of the foregoing CVS Health-affiliated entities is a Co-Conspirator with Biogen in the unlawful conduct alleged herein. Co-Conspirators CVS Health, Caremark Rx, LLC, Caremark, LLC, CVS Specialty Pharmacy, and Aetna are collectively referred to herein as “CVS Caremark.”

39. Co-Conspirator The Cigna Group (“Cigna”) is a corporation organized and existing under the laws of the state of Delaware, with its principal place of business located in Bloomfield, Connecticut. Cigna is a healthcare behemoth that owns and controls, among other entities, a major health insurer, one of the top three PBMs, a specialty pharmacy, and a mail-order pharmacy. Evernorth Health, Inc. (“Evernorth”), formerly known as Express Scripts Holding Company, is a Delaware corporation with its principal place of business in St. Louis, Missouri and is a wholly owned subsidiary of Cigna. In 2018, Express Scripts Holding Company merged with Cigna Corporation (“Cigna”) in a \$67 billion deal to consolidate their businesses as a major health insurer, PBM and mail-order pharmacy.

40. Cigna owns, directly or indirectly, Evernorth, Express Scripts, Inc., and Express Scripts Administrators, LLC, (collectively referred to as “ESI”) which provide or are directly involved with providing PBM services; Accredo Health Group, Inc. d/b/a Accredo Specialty Pharmacy (“Accredo”), the specialty pharmacy; and Express Scripts Pharmacy, the mail-order pharmacy. ESI and Express Scripts Pharmacy each has its principal place of business at the same location as Evernorth. Accredo’s principal place of business is located in Memphis, Tennessee. Each of the foregoing Cigna-affiliated entities is a Co-Conspirator with Biogen in the unlawful conduct alleged herein. Co-Conspirators Cigna, ESI, Accredo, and Express Scripts Pharmacy are collectively referred to herein as “Express Scripts.”

41. Co-Conspirator UnitedHealth Group, Inc. (“UHG”) is a corporation organized and existing under the laws of the state of Delaware, with its principal place of business in Minnetonka, Minnesota. It is a healthcare behemoth that owns and controls, among other entities, a major health insurer, one of the top three PBMs, a specialty pharmacy, and a mail-order pharmacy.



42. Co-Conspirator OptumRx, Inc. has its principal place of business in Irvine, California and is a wholly-owned direct subsidiary of OptumRx Holdings, LLC, which is a limited liability company incorporated under the laws of Delaware. OptumRx, Inc. and OptumRx Holdings, LLC provide pharmacy benefit management services under the OptumRx name that represents UHG's PBM business.

43. Co-Conspirator OptumRx Holdings LLC is a wholly-owned, direct subsidiary of Optum, Inc. And Co-Conspirator Optum, Inc. is a wholly-owned indirect subsidiary of UHG and incorporated under the laws of Delaware. Optum, Inc., promotes itself as a URAC-accredited specialty pharmacy and mail service pharmacy with more than 30 accredited sites.

44. Optum, Inc. and the following specialty pharmacy and mail service pharmacy sites are collectively referred to herein as "Optum Specialty Pharmacy": OptumRx, Inc.; Optum Infusion Services 101 Inc.; Optum Infusion Services 103 LLC; Optum Infusion Services 200 Inc.; Optum Infusion Services 202 Inc.; Optum Infusion Services 203 Inc.; Optum Infusion Services 204 Inc.; Optum Infusion Services 207 Inc.; Optum Infusion Services 209 Inc.; Optum Infusion Services 302 LLC; Optum Infusion Services 305 LLC; Optum Infusion Services 308 LLC; Optum Infusion Services 401 LLC; Optum Infusion Services 404 LLC; Optum Infusion Services 500 Inc.; Optum Infusion Services 501 Inc.; Optum Infusion Services 501 LLC; Optum Infusion Services 550 LLC; Optum Infusion Services 553 LLC; Optum Pharmacy 701 LLC; Optum Pharmacy 704, INC.; Optum Pharmacy 700 LLC; Optum Specialty Services, LLC; Optum Specialty Distribution, LLC; BriovaRx of Florida, Inc.; BriovaRx of Maine, Inc.; BriovaRx of Massachusetts, LLC; Diplomat Pharmacy, Inc. d/b/a Diplomat Specialty Pharmacy; Leehar Distributors, LLC; and Salveo Specialty Pharmacy, Inc.

45. Each of the foregoing UHG-affiliated entities is a Co-Conspirator with Biogen in the unlawful conduct alleged herein. Co-Conspirators UHG, OptumRx Holdings LLC, OptumRx, Inc., and Optum Specialty Pharmacy are collectively referred to herein as “OptumRx.”

46. All of the Co-Conspirators CVS Caremark, Express Scripts and OptumRx, are collectively referred to herein as “PBMs,” and their wrongful actions described in this Complaint are part of, and in furtherance of, the unlawful restraints of trade alleged herein, and were authorized, ordered, and/or undertaken by the Co-Conspirators’ various officers, agents, employees, or other representatives while actively engaged in the management of the Co-Conspirators’ affairs (or that of their predecessors-in-interest) within the course and scope of their duties and employment, and/or with the actual, apparent, and/or ostensible authority of the Co-Conspirators.

### **III. JURISDICTION AND VENUE**

47. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332(d) because this is a class action in which the aggregate amount in controversy exceeds \$5,000,000 and at least one member of the putative class is a citizen of a state different from that of Biogen.

48. This Court also has jurisdiction over this matter pursuant to 15 U.S.C. § 26 and 28 U.S.C. §§ 1331 and 1337 in that Plaintiffs bring claims under Section 16 of the Clayton Act, 15 U.S.C. § 26, for injunctive and equitable relief to remedy Biogen’s violations of Sections 1 and 2 of the Sherman Antitrust Act, 15 U.S. C. § 1 and 2, and under Section 4(a) of the Clayton Act, 15 U.S.C. § 15(a), for damages and other relief to remedy Biogen’s violations of Sections 1 and 2 of the Sherman Antitrust Act, 15 U.S. C. § 1 and 2 and of Section 2(c) of the Robinson-Patman Act,

15 U.S.C. § 13(c). The Court has supplemental jurisdiction over Plaintiffs' pendent state law claims pursuant to 28 U.S.C. § 1367.

49. This Court has personal jurisdiction over Biogen under Section 12 of the Clayton Act, 15 U.S.C. § 22. The Court also has personal jurisdiction over Biogen under the Illinois long-arm statute, 735 ILCS 5/2-209(a)(7). The claims of Plaintiffs and the Class members arise out of or relate to Biogen's conduct in this district. Plaintiffs and certain class members made relevant purchases here; Biogen employs salespeople based in this district to market Biogen's products, including convincing doctors here to prescribe Tecfidera and Vumerity; Biogen advertises Tecfidera and Vumerity to people living in this district, including running a national television advertising campaign for Tecfidera that targeted and reached residents of this district; and Biogen's unlawful conduct caused PBMs to disadvantage generic Tecfidera on formularies covering residents of this district and caused health plans and consumers in this district and elsewhere to incur overcharges on their purchases covered by those formularies.

50. Venue is appropriate within this district under Section 12 of the Clayton Act, 15 U.S.C. § 22, and under 28 U.S.C. §1391(b) and (c), because Biogen transacts business within this district and the interstate trade and commerce, hereinafter described, is carried out, in substantial part, in this district.

#### **IV. THE IMPORTANCE OF GENERIC DRUGS**

##### **A. The High Price of Branded Drugs**

51. The marketplace for the sale of prescription pharmaceutical products in the United States suffers from a significant imperfection that brand manufacturers can exploit to get or maintain market power in the sale of a particular pharmaceutical composition. Markets function best when the person responsible for paying for a product is also the person who chooses which product to purchase. When the same person has both the payment obligation and

the choice of products, the product's price plays an appropriate role in the person's choice of products and, consequently, the manufacturers have an appropriate incentive to lower their prices.

52. The pharmaceutical marketplace, however, is characterized by a “disconnect” between the payment obligation and the product selection. State laws prohibit pharmacists from dispensing many pharmaceutical products, including Tecfidera and Vumerity, to patients without a prescription written by a doctor. The prohibition on dispensing the drug without a prescription introduces a disconnect between the payment obligation and the product selection. The patient (and in most cases his or her insurer) has the obligation to pay for the drug, but the patient's doctor chooses which drug the patient will buy.

53. Biogen and other brand manufacturers exploit this price disconnect by employing large forces of sales representatives to visit doctors' offices and persuade them to prescribe the manufacturer's products. These sales representatives do not advise doctors of the cost of the branded products. Moreover, studies show that doctors typically are not aware of the relative costs of brand pharmaceuticals and, even when they are aware of the relative costs, they are insensitive to price differences because they do not have to pay for the drugs. The result is a marketplace in which price plays a comparatively unimportant role in product selection.

54. The relative unimportance of price in the pharmaceutical marketplace reduces what economists call the price elasticity of demand—a measure of the extent to which unit sales go down when price goes up. This reduced price elasticity in turn gives brand manufacturers the ability to raise price substantially above marginal cost without losing so many sales as to make the price increase unprofitable. The ability to profitably raise price substantially above marginal cost is what economists and antitrust courts refer to as market power.

55. The result of the market imperfections and marketing practices described above is that brand manufacturers gain and maintain market power with respect to many branded prescription pharmaceuticals.

**B. The Regulatory Structure that Promotes Generic Drugs**

56. The relevant drug-regulation framework is established by the Federal Food, Drug, and Cosmetic Act (“FDCA”), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (“Hatch-Waxman Amendments”). Under FDCA, branded drug manufacturers that wish to sell a new drug product must obtain approval from the FDA by filing a New Drug Application (“NDA”). 21 U.S.C. § 355(b). The NDA must include, among other things, a statement of the drug’s components, active ingredients, scientific data showing that the drug is safe and effective, patent information, and proposed labeling describing the methods by which a drug may be used and administered. 21 U.S.C. §§ 355(a), (b).

57. Upon FDA approval of the NDA, the FDA lists any patents that the manufacturer asserts could reasonably be enforced against a generic manufacturer that makes, uses, or sells a generic version of the brand drug before the listed patents expire. The FDA relies completely on the brand manufacturer’s truthfulness about patent validity and applicability, because it does not have the resources or authority to verify the manufacturer’s patents for accuracy or trustworthiness.

58. The Hatch-Waxman Amendments speed generics onto the market. The Amendments’ fundamental premise is that many branded prescription drugs have market power and that only competition from generic drugs can bring competitive prices. The evidence on which Congress relied showed that, even after brand-drug patents had expired, competition

among branded drugs was insufficient to deliver competitive prices. Only competition from generic drugs could drive prices to the competitive level.

59. The Amendments speed generics onto the market several ways. The Amendments simplify the regulatory hurdles for generic manufacturers by eliminating the need for them to file lengthy and costly NDAs. Instead, generic manufacturers can file an Abbreviated New Drug Application (“ANDA”), which relies on the scientific findings of safety and effectiveness included in the brand manufacturer’s original NDA. The generic manufacturer need only show that the generic drug contains the same active ingredient(s), dosage form, route of administration, and strength as the brand drug, and is absorbed at the same rate and to the same extent as the brand drug—that is, that the generic drug is pharmaceutically equivalent and bioequivalent (together, “therapeutically equivalent”) to the brand drug. The FDA assigns generic drugs that are therapeutically equivalent to their brand-name counterpart an “AB” rating.

60. The FDCA and Hatch-Waxman Amendments operate on the basis that bioequivalent drug products containing identical amounts of the same active ingredients, having the same route of administration and dosage form, and meeting applicable standards of strength, quality, purity and identity, are therapeutically equivalent. Bioequivalence demonstrates that the proposed generic drug’s active ingredient would be present in the patient’s blood to the same extent and for the same amount of time as the branded counterpart. 21 U.S.C. § 355(j)(8)(B). So a generic drug that receives an AB rating from the FDA may safely be substituted for the brand drug.

61. In addition to easing FDA approval for generic drugs, the Hatch-Waxman Amendments also eased their pathway through litigation over the brand manufacturer’s patents. A generic manufacturer that certifies that its product will not infringe the brand’s patents may be

able to litigate the patents' validity and applicability without subjecting itself to patent-infringement damages if it were to lose the litigation. 21 U.S.C. § 355(j)(2)(A)(vii)(IV). And Congress encouraged manufacturers to challenge brand-drug patents, providing a valuable period of generic-drug exclusivity—essentially, a financial bounty often worth hundreds of millions of dollars—for the first manufacturer that initiates a challenge to such a patent. 21 U.S.C. § 355(j)(5)(B)(iv) and 21 U.S.C. § 355(j)(5)(D).

62. State legislation has supplemented Congress's efforts to speed generics onto the market. Since passage of the Hatch-Waxman Amendments, every state has adopted substitution laws that either require or permit pharmacies to substitute AB-rated generic equivalents for branded prescriptions (unless the prescribing physician has specifically ordered otherwise).

63. Like the Hatch-Waxman Amendments, these state drug-product selection laws are founded on the premise that, before generic entry, branded drugs typically have market power. If they did not have market power, there would be little or no need for state laws that permit or require the pharmacist to substitute a generic.

64. The combined federal and state efforts to promote generic competition—when not undermined by manufacturers' or others' anticompetitive conduct—have been largely successful. In 1983, before the Hatch-Waxman Amendments and state generic-substitution laws, only 35% of the top-selling drugs with expired patents had generic alternatives; by 1998, nearly all did. By 2013, generic drugs accounted for 86% of all prescriptions dispensed. Today, generics are dispensed 95% of the time when a generic version is available.

### **C. The Competitive Effects of AB-rated Generic Competition**

65. Generic versions of brand name drugs contain the same active ingredient, and are determined by the FDA to be just as safe and effective as their brand-name counterparts. The

only material difference between generic drugs and their corresponding brand-name versions is their price.

66. Generic versions of a corresponding branded drug product are commodities that cannot be differentiated, so the primary basis for generic competition is price. Typically, generics are at least 25% less expensive than their brand-name counterparts when there is a single generic competitor, and this discount typically increases to 80% (or more) when multiple generic competitors are on the market for a given brand. Consequently, the launch of a generic drug usually results in significant cost savings for all drug purchasers.

67. Once a generic equivalent hits the market, the generic quickly takes sales from the corresponding branded drug, often capturing 90% or more of the market within the first six months, and 95% or more during the first 12 months. As a result, brand drug companies, including Biogen, view competition from generic drugs as a grave threat to their bottom lines.

68. By impairing generic competition, the brand manufacturer can continue to profitably charge supracompetitive prices. Brand manufacturers, including Biogen, are well aware of generics' rapid erosion of their brand sales. Brand manufacturers therefore try to extend their monopoly for as long as possible by impairing generic competition, sometimes resorting to any means possible—including illegal means.

## **V. THE PROMISE AND PERILS OF PBMS**

69. PBMs manage prescription drug benefits on behalf of their clients, which include health insurance companies, self-funded health plans, large companies, and governmental entities.

### **A. The Promise**

70. One of the principal roles for PBMs is to create and maintain a drug formulary for the PBM's clients. A formulary is a list of prescription drugs for which the health plan will



reimburse pharmacies on behalf of the plan's members. The formulary also describes the copayment or coinsurance for which the covered patient is responsible. A proper formulary will almost always provide a lower copayment or coinsurance for generic drugs as compared to their brand-drug counterparts. This incentivizes the patients to demand or accept the generic drug.

71. The purpose behind a proper drug formulary is to provide quality care using the most cost-effective options. If a drug is not included on a formulary, the health plan generally will not cover the cost of the drug. Thus, if a doctor prescribes a drug that is not on the formulary, the patient will be required to pay the entire cost of the drug out-of-pocket.

72. Prominent among PBMs' proper roles is to aggressively promote the use of generic drugs whenever possible. As noted above, generic drugs can quickly deliver discounts of 90% or more off the price of the branded drug.

73. A properly acting PBM has several powerful tools available to promote insureds' use of generic drugs when they are available. Important among these is placing the generic on the most advantageous tier on the formulary.

74. When rival drugs are available to treat the same condition, a PBM's formulary may prefer certain of those drugs over other "non-preferred" drugs. When PBMs are not bribed to do otherwise, their formularies use a "tier" system to promote effective but less costly drug alternatives.


75. PBMs place drugs into different tiers on their formularies, with five tiers being typical. Generally, drugs in a lower-numbered tier cost beneficiaries less than drugs in higher-numbered tiers, with generic drugs on the lowest-numbered tier and brand-name and specialty drugs on a higher-numbered tier. For example, tier 1 may include most generic prescription

drugs, while tier 5 may include specialty drugs, which include high-cost prescription drugs with the highest cost-sharing.

76. Formularies typically provide for lower patient cost-sharing—the amount the insured must pay through co-payments or coinsurance—for drugs on the lowest-numbered (i.e., the best) tier. Properly acting PBMs almost always promote generic drugs by placing them on Tier 1.

77. For both generic and brand-name drugs, PBMs may offer preferred and non-preferred tiers. Drugs in preferred tiers are generally more cost-effective than drugs in non-preferred tiers. Preferred brand-name and generic drugs also generally have lower cost-sharing than non-preferred brand-name and generic drugs.

78. Cost sharing can vary substantially by tier. For example, among those in plans with four tiers, average cost-sharing ranged from \$12 copayment or 20% coinsurance for first tier/preferred drugs to a \$124 copayment or 32% coinsurance for fourth tier drugs. Such tiering promotes the use of lower cost drugs that are more accessible, such as generics, on the lower tiers compared to the more costly nonpreferred brand drugs typically included on the higher tiers.



Tier	Drug type	Cost to beneficiary
1	Preferred generics	\$
2	Generics	\$\$
3	Preferred brands	\$\$\$
4	Non-preferred	\$\$\$\$
5	Specialty	\$\$\$\$\$

Source: GAO; GAO (illustrations). | GAO-23-105270

79. In addition to formulary tiers, PBMs can promote generic drug use by implementing drug utilization management tools. These tools promote generic drugs over brands by imposing policies on prior authorization (which involves a review and sign-off by a PBM-

employed health care provider before a patient can obtain a prescribed drug), step therapy (which requires a patient to try a preferred option on the formulary before the insurer will cover the originally-prescribed drug), and quantity limits (such as restricting the number of doses a patient can receive for a particular condition).

80. Promoting generic drugs instead of brands is a principal way for PBMs to control drug costs for health plans and patients. In 2020 alone, the use of generic medicines saved the healthcare system an estimated \$313 billion. On average, patients pay only \$6.97 out of pocket for generic medicines, with over 90% of generic prescriptions costing patients less than \$20 in 2020.

81. PBMs also create pharmacy networks through which the insureds get their covered prescriptions filled. This typically includes mail order pharmacies in addition to “brick and mortar” pharmacies.

82. In sum, through their control of formularies and pharmacy networks, PBMs have a prominent role in determining which drugs will be accessible to patients and at what cost.




## **B. The Perils**

83. Over the past 20 years, the PBM marketplace has become increasingly concentrated. In 2004, the top three PBMs served a combined 190 million people and managed 52% of prescription drug claims. Today, the three PBMs manage about 80% of prescription drug claims, for about 270 million people. With some overlap among them the top three PBMs are: CVS Caremark, which manages the claims of 103 million people; ESI, which manages the claims of more than 100 million people; and OptumRx, which manages the claims of over 66 million people.

84. The high concentration of these massive companies is further exacerbated by the concentration in common ownership of each. The ownership of each PBM parent organization (UHG, CVS Health Corporation, and Cigna) includes the same six companies among their top 10 Institutional Holders. Together, these six shareholders own 27% to 32% of each PBM parent organization, owning nearly one-third of the companies' combined \$819.5 billion market value. This common ownership reduces competition by diminishing incentives to compete and increasing the ability to share competitively sensitive information.

85. Each of the three PBMs has become vertically integrated with various entities along the pharmaceutical supply chain, insulating them from competition by creating barriers to entry for any non-integrated entity that wants to provide competing PBM services. This gives them even greater power and control over the distribution and pricing of drugs than their dominance in PBM services alone already provides. Each PBM's vertical integration gives it near complete control of the pricing, dispensing, and reimbursement system for all prescription drugs for its covered lives. This control permits the PBM to work with drug manufacturers to drive up drug prices and foreclose patients' access to competitors' less costly drugs. The result is increased profits for the PBMs and brand manufacturers, and higher drug prices for consumers and health plans.

86. This graphic depicts each PBM's vertical integration with midstream distributors, including retail, mail order, and specialty pharmacies. Each is also vertically integrated with a health insurer that controls drug coverage for hundreds of millions of Americans.

Parent/Owner	CVS Health Corporation	The Cigna Group	UnitedHealth Group Inc.
Drug Private Labeler	Cordavis Limited	Quallent Pharmaceuticals	NUVAIRA
Health Care Provider	MinuteClinic, Signify Health	Evernorth Care Group	Optum Health
Pharmacy Benefit Manager			
"PBM GPO"/Rebate Aggregator	Zinc Health Services	Ascent Health Services	Emisar Pharma Services
Pharmacy - Retail	CVS Pharmacy		
Pharmacy - Mail Order	CVS Caremark Mail Service Pharmacy	Express Scripts Pharmacy	Optum Rx Mail Service Pharmacy
Pharmacy - Specialty	CVS Specialty Pharmacy	Accredo	Optum Specialty Pharmacy
Health Insurer	Aetna	Cigna Healthcare	UnitedHealthcare

87. Especially relevant here are the “specialty pharmacies” that the PBMs sometimes include in their pharmacy networks. A specialty pharmacy primarily dispenses “specialty drugs” and may be a brick-and-mortar pharmacy or a mail order pharmacy. The vast majority are mail order pharmacies. Historically, specialty drugs were characterized by their need for special handling and administration.

88. Today, however, PBMs exercise unregulated discretion in classifying drugs as specialty medications. Some PBMs designate a drug as specialty based solely on its high cost. When a PBM vertically integrates with a specialty pharmacy, it has an increased ability to steer patients to its own in-house specialty pharmacy and toward more expensive drugs—in exchange for payments from brand manufacturers.

89. The prescriptions having been steered into a limited-distribution channel—shielded from the retail-level competition provided by the nation’s tens of thousands of retail pharmacies—the PBM-affiliated specialty pharmacies can and do charge outrageous prices to patients and health plans for those drugs. It is not unusual for those specialty pharmacies to charge prices 20-40 times higher than their acquisition costs.

90. Specialty drugs account for a growing share of pharmacy dispensing revenue (about 40-50%) but only a small fraction of total prescription volume (about 2%). A PBM’s designating a product as a specialty drug may trigger provisions in its contract with a health plan that require the insureds to fill the prescription only at the PBM’s affiliated specialty pharmacy. The three PBMs’ specialty pharmacies account for nearly 70% of all specialty-drug revenue.

91. In 2023, CVS Specialty, owned by CVS Health, earned \$73.3 billion in revenues from specialty drugs, which accounted for 30% of all prescription revenues from specialty drugs. Accredo, owned by Cigna/Evernorth, earned \$59.5 billion in revenues from specialty drugs, which accounted for 24% of all prescription revenues from specialty drugs. And Optum Specialty Pharmacy, owned by UnitedHealth Group, earned \$32.3 billion in revenues from specialty drugs, which accounted for 13% of all prescription revenues from specialty drugs. Overall, mail order pharmacies accounted for more than three-quarters of the industry’s \$243 billion in total prescription revenues from specialty drugs.

92. Other economic trends in the PBM marketplace confirm that the consolidation and vertical integration in the PBM industry has warped PBMs’ incentives, diminished competition among them, and set the stage for brand-drug manufacturers to cause economic harm to drug purchasers.

93. For example, the PBMs have begun accepting rebates and “fees” from brand manufacturers in exchange for skewing their formularies to favor higher-priced brand drugs over low-cost generic drugs. The brand manufacturers and PBMs win; patients and health plans lose. Similarly, by prioritizing specialty and branded drugs over generics, PBMs can raise drug prices and push consumers toward more expensive options, decreasing the use and availability of lower-cost generics.

94. The PBMs and brand manufacturers, including Biogen, have created a “hide-the-ball” system where the consideration that the manufacturer pays to the PBMs (and does not share with payors) is labeled and relabeled. As more health plans required PBMs to pass a majority of the manufacturer “rebates” through to them, PBMs started renaming the payments in order to keep a larger portion of them. Payments once known as “rebates” are now called administrative fees, volume discounts, service fees, data usage fees, inflation fees, or other industry jargon terms designed to obfuscate and distract from the substantial sums being secretly exchanged.

95. The PBMs perform no services for these unearned fees or payments. In return for these fees paid by brand manufacturers, including Biogen, the only thing the PBMs do is disadvantage and suppress lower cost drugs.

96. PBMs have also begun using “rebate aggregators” to negotiate the payments they will receive from the brand manufacturers. Using rebate aggregators allows the PBMs to hide the payments from regulators and the health plans. PBMs have recently doubled the amount of fees they get from drug manufacturers, from \$3.8 billion in 2018 to \$7.6 billion in 2022.

97. The PBMs carefully guard the revenue streams they receive from their rebate aggregator activities, hiding them in complex contractual relationships and not reporting them separately in their quarterly SEC filings.

98. Further reducing transparency, and making oversight more difficult, two of the three PBMs have located their affiliated aggregators offshore. Express Scripts located its aggregator, Ascent Health, in Switzerland. OptumRx located its aggregator, Emisar Pharma Services, in Ireland.

99. A recent study by the Pew Charitable Trust estimated that, between 2012 and 2016, the amount of administrative and other fees that the PBMs requested and received from the brand manufacturers tripled, reaching more than \$16 billion. That growth in “fees” has continued to accelerate since 2016.

100. In short, health plans cannot defeat the PBMs’ accepting payments from brand manufacturers. Health plans may choose which pharmacy networks and drug formularies to use, but information asymmetries hinder their ability to make fully informed decisions. So most health plans accept the standard formularies that the PBMs offer or otherwise defer to their formulary recommendations. Indeed, health plans hire PBMs for their expertise, including in formulary management.

101. From 2016 to 2023, the total revenues of the CVS healthcare conglomerate rose from \$177.5 billion to \$357.8 billion. Those of the Cigna healthcare conglomerate rose from \$39.7 billion to \$195.3 billion, and those of the United Healthcare conglomerate rose from \$184.8 billion to \$371.6 billion. They also expanded their operating profits; the three conglomerates’ combined profits rose from \$31.4 billion in 2016 to more than \$58.4 billion in 2023.

102. PBMs began as a partial solution to the problem of brand-drug manufacturers’ market power. Formularies and other competitive tools were capable of generating some competition among branded drugs, and of promoting generic drugs after brand-drug patents



expired. But once these commercial behemoths achieved dominance up and down the pharmacy distribution chain, they have proved only too willing to wield that dominance as a mechanism of exclusion at the behest of brand-drug manufacturers. In exchange for payments from the brand-drug manufacturers, the PBMs have thwarted the generic competition that is their legitimate role to promote.

## **VI. BRAND MANUFACTURERS' ANTICOMPETITIVE TACTICS**

103. Over the years, brand manufacturers have developed an arsenal of anticompetitive tactics to impair generic competition. Two are most relevant here.

### **A. Market Switches**

104. One tactic to impair generic competition is to prevent the generic drug from being AB-rated to the brand drug, thereby preventing automatic generic substitution. The AB-rating requirement for generic drugs is designed to ensure therapeutic equivalence to the reference (brand) product. It is concerned only with safety and efficacy, not with effects on competition.

105. Regulations permit brand manufacturers to seek FDA approval to modify the dosage form and strength of their existing products. An unscrupulous brand manufacturer that anticipates the onset of generic competition to its drug can modify the dosage form, strength, or some other characteristic of its product from, say, A to A<sub>1</sub>, for the purpose of preventing the anticipated generic product from being AB rated to the new brand product. Before the generic manufacturer receives FDA approval for the generic version of A and enters the market, the brand manufacturer can get approval for A<sub>1</sub> and cannibalize the sales of A—use its massive sales force to get doctors to switch their prescriptions from A to A<sub>1</sub>.

106. Thus, before the generic of A enters the market the brand manufacturer will have: (a) ensured that the generic product cannot be AB rated to, and substitutable for, A<sub>1</sub>; and (b)

switched the prescription base from A to A<sub>1</sub>. Consequently, when the generic finally gets FDA approval to enter the market, it will garner substantially reduced sales because it is not substitutable for the new brand product to which the brand manufacturer has switched the prescription base.

107. The timing of the switch is critical. It is well known in the pharmaceutical industry that if generic versions of the original brand product enter the market before the branded follow-on product, the latter will make very few sales unless it offers substantial, demonstrable medical benefits to consumers. For example, one brand manufacturer estimated that it would make ten times more sales of its branded follow-on product if it beat generic versions of the original product onto the market. In a detailed inquiry into the pharmaceutical industry, the European Commission concluded that “it is of utmost importance for the originator company to bring the follow-on product on the market before the first product effectively loses exclusivity.” European Commission, Final Report, p. 356 (8 July 2009), [http://www.europa-nu.nl/id/vi6wcj7amsx3/pharmaceutical\\_sector\\_inquiry\\_fianl?start-006-00c=10](http://www.europa-nu.nl/id/vi6wcj7amsx3/pharmaceutical_sector_inquiry_fianl?start-006-00c=10). Industry analysts in the United States have reached the same conclusion, warning brand manufacturers that it is essential that they switch patients to the new formulation before the generic enters.

108. It is equally well known that, after a market switch, doctors are unlikely to prescribe the original product—in this case, Tecfidera. Having switched their prescribing habits from the original to the reformulated product—and having switched specific patients’ medications from the original to a reformulated product—most doctors will not switch their prescribing habits or their patients back to the original product after the generic is available. In economic terms, switching costs (e.g., the need for another visit to the doctor for a new

prescription) impair a move back to the original product. And pharmaceuticals are “experience” goods that consumers and physicians are hesitant to change if they are working.

109. Brand manufacturers know that, if they successfully cannibalize the original product’s sales before the generics enter the market, the generics are not likely to *ever* compete effectively for those switched prescriptions. Automatic substitution at the pharmacy counter is a generic product’s only commercially viable means of competing. Once the brand’s patents are no longer effective, *no one*—neither the brand manufacturer nor any generic manufacturers—can profitably market the product on a basis other than price. Costs incurred to encourage a doctor to write a prescription for the firm’s own product would be squandered because the pharmacist can fill the prescription with a competitor’s AB-rated product.

110. And this is a good thing. If a manufacturer could profitably market the product to doctors on a basis other than price, this would merely replicate the price-disconnect failure in these markets. The price disconnect is the problem, and AB-rated substitution at the pharmacy counter is the solution. The generic-substitution regime is *designed* to render it unprofitable to actively market the product to doctors.

111. Once the market switch is done, pharmacists are unable to dispense the generic drug through the efficient mechanism of automatic substitution because the dosage form and/or dosage amount is different. Thus, in most instances, the generic’s opportunity to compete for those sales is gone forever.

## **B. Kickbacks to PBMs**

112. The recent changes in the PBM industry have set the stage for brand-drug manufacturers to enlist PBMs in impairing rather than promoting generic competition. The

vertical integration and market concentration have made it profitable for the PBMs to accept kickbacks from the brand manufacturers to impair generic competition.

113. The basic economics demonstrate why.

114. The brand manufacturer and the PBMs have a collective economic interest in impairing generic competition. If they work together to hinder generic competition, they can keep the profit margins on all the unit sales high and split the resulting excess profits among themselves. They can keep the enormous savings that generic competition would have delivered to drug purchasers. The following series of pie charts demonstrates the brand manufacturer's and PBMs' collective interest in reducing generic competition.

115. A brand manufacturer in the marketplace without competition from generics gets all of the profits on all of the unit sales:

## BRAND HAS ALL PROFITS

### Before Generic Entry



116. When generic entry occurs, the brand manufacturer loses most of the unit sales; the generic manufacturers sell most of the units, but at drastically reduced prices; and competition delivers enormous savings to drug purchasers. Competition converts what formerly were excess profits into purchaser savings:

### GENERIC COMPETITION DELIVERS SAVINGS TO PURCHASERS

**Generic Competition**



117. To avoid this result, the brand manufacturer can pay the PBM to impair generic competition. The reduced competition keeps the brand manufacturer's profits high, and the manufacturer can use a portion of those extra profits to make the payment to the PBM. The brand manufacturer and the PBM win; the purchasers lose:

**PAYOFFS TO PBMS DIVIDE PURCHASER SAVINGS BETWEEN  
BRAND MANUFACTURERS AND PBMS**

**Payoff to Disadvantage Generics**



118. In order for this anticompetitive pact to work, the brand manufacturer needs a means by which to divide the extra profits with the PBM. The PBM will not help impair generic competition if it does not share in the ill-gotten gains. Kickbacks from the brand manufacturer are the way it divides the ill-gotten gains with the PBM.

119. As explained in detail below (see Sections VIII and IX), this case involves a cynical combination of these two generic-impairing tactics—a market switch enabled by kickbacks to the PBMs.

120. Biogen paid kickbacks—denominated as rebates and/or fees—to each of the Co-Conspirator PBMs. In exchange, the PBMs agreed not to favor lower cost generic Tecfidera over branded Tecfidera or Vumerity. Moreover, this arrangement had the intended effect of causing each of the PBMs to designate generic Tecfidera as a “specialty drug.” That designation had devastating financial consequences for health plans and patients.

## **VII. BIOGEN'S DEVELOPMENT AND SALES OF TECFIDERA AND VUMERITY**

### **A. Multiple Sclerosis Is a Chronic Disease for Nearly One Million Americans.**

121. MS is a chronic autoimmune disease that affects the central nervous system. The disease is characterized by the immune system's attacking the protective sheath (myelin) that covers nerve fibers, leading to communication problems between the brain and the rest of the body. Almost one million people in the United States have been diagnosed with MS.

122. Although the symptoms and signs of MS can vary, the interruption of signals to the brain generally causes numbness, blindness, mood changes, memory problems, pain, fatigue, and/or paralysis. Other symptoms include lack of coordination, unsteady gait or inability to walk, prolonged double vision, blurry vision, vertigo, slurred speech, and cognitive problems.

123. MS most commonly presents in the relapsing remitting form. Patients will go through cycles of disease flair ups, experiencing symptoms that typically improve fully or partially over time. Remission of the disease tends to follow flair ups, but the length of remission varies.

124. The cost of living with MS is very high. Direct medical costs such as doctor's appointments and the cost of drugs are some of the biggest contributors to the high cost of living with MS. There is no cure for MS.

### **B. Biogen Made Billions Selling Tecfidera for More Than \$90,000 Per Patient Per Year.**

125. Biogen is a global biopharmaceutical company that manufactures, promotes, and distributes prescription drugs. On March 19, 2013, the U.S. Patent and Trademark office issued a patent for Tecfidera (dimethyl fumarate). In the same year, the FDA approved Tecfidera for the treatment of MS, and it quickly became one of Biogen's top-selling drugs. Biogen touted

Tecfidera's effectiveness in reducing MS relapses, delaying the progression of physical disability associated with MS, and slowing the development of MS-related brain lesions.

126. By 2015, Biogen's U.S. sales for Tecfidera were \$2.9 billion, which was nearly half of Biogen's total U.S. product sales (\$6.5 billion) for that year. Tecfidera's significant contribution to Biogen's U.S. sales continued throughout the rest of the decade:

<b>Year</b>	<b>Tecfidera US Sales</b>	<b>Total Biogen US Product Sales</b>
2016	\$3.1 billion	\$7.0 billion
2017	\$3.2 billion	\$7.0 billion
2018	\$3.2 billion	\$6.8 billion
2019	\$3.3 billion	\$6.7 billion

127. Biogen consistently raised Tecfidera's price to increase its total revenue and profits. For example, according to Biogen's 2016 Annual Report, "the increase in U.S. Tecfidera revenues was primarily due to price increases, partially offset by higher discounts and allowances and a decrease in unit sales volume of 1%." Biogen's Annual Reports likewise cited price increases as the reason for increased Tecfidera sales revenue from 2016 to 2017 and from 2018 to 2019.

128. Consequently, as of 2019 the average price of Tecfidera was \$124.67 per pill (approximately \$90,000 for an annual supply at two pills per day), up from an original 2013 price of about \$71.87 per pill (approximately \$52,500 for an annual supply at two pills per day)—a 73.5% increase. During that same period, the Consumer Price Index increased by only 9.7%.

129. Health plans allocated substantial financial resources to cover Tecfidera for their members. They assume the financial risk associated with providing healthcare benefits to their employees and members. Outrageously expensive drugs like Tecfidera (and, later, Vumerity)



place an enormous financial strain on these plans, including especially the plans sponsored by small-to-mid-sized employers and union health and welfare plans.

130. From 2013 until generic Tecfidera became available in 2020, branded Tecfidera was essentially a must-have for any formulary. It is a life-saving and life-altering drug, so PBMs had little choice but to include Tecfidera on their formularies. Excluding Tecfidera would have meant denying access to a primary therapy for MS patients.

131. All of that would change when generic Tecfidera became available.

## **VIII. BIOGEN'S PLAN TO DEFEAT GENERIC COMPETITION**

### **A. Biogen Planned to Defeat Generic Competition with an "Evergreen" Strategy.**

132. Beginning in 2017, Biogen found itself on the defensive as it confronted a series of challenges to its patent on Tecfidera. These patent challenges threatened Tecfidera's patent protections, which Biogen had relied on to secure its market exclusivity and significant revenue streams. Biogen knew that, if the patent challenges succeeded, early entry of generic competition would significantly reduce its profitability from this key product.

133. So Biogen developed a strategy to maintain the monopoly profits from its Tecfidera franchise even if its patent were invalidated. The plan was to "evergreen" the franchise by moving the Tecfidera prescriptions to a follow-on product before generic Tecfidera became available.

134. That follow-on product was Vumerity (diroximel fumarate). The development journey of Vumerity began with a U.S. patent application submitted in September 2013 by Alkermes plc, a Dublin-based pharmaceutical firm. This patent was issued on March 31, 2014 and expires on October 29, 2033.

135. Alkermes developed the formulation of diroximel fumarate in partnership with Biogen. Despite this early start in development, Biogen did not file a New Drug Application (“NDA”) for diroximel fumarate until December 2018. The FDA granted approval for the drug in October 2019.

136. The way in which Biogen obtained FDA approval for Vumerity confirms that it is medically equivalent to Tecfidera. Biogen got FDA approval of Vumerity by using the studies that showed that *Tecfidera* was safe and effective. Biogen submitted studies showing that Vumerity is bioequivalent to Tecfidera.

137. Vumerity is diroximel fumarate, while Tecfidera is dimethyl fumarate. Although diroximel fumarate and dimethyl fumarate have different chemical structures and pharmacokinetic properties (how they are absorbed, distributed, and eliminated), the body rapidly converts both of them to the same active ingredient — monomethyl fumarate. It is that active ingredient that provides the drugs’ therapeutic effects.

138. Similarly, the dosing regimens for the two medications share a common therapeutic strategy, which involves starting the patient on a lower dosage before escalating to a higher maintenance dose. A lower starting dosage allows the body to adjust to the new medication. Each Vumerity pill is 231mg. To start, the patient takes one pill (231mg) twice a day orally for 7 days. After 7 days, the patient increases the dosage to 2 pills (462mg) twice a day orally for maintenance. The Tecfidera starter pack includes pills that are 120mg each. To start, the patient takes one pill (120mg) twice a day orally for 7 days. After 7 days, the patient starts the maintenance dosage. This dosage contains pills that are 240mg each. And the patient takes one pill (240mg) twice a day orally for maintenance.

139. Biogen began selling Vumerity in 2019, marketing it on the asserted ground that it leads to fewer side effects—gastrointestinal problems—compared to Tecfidera. Medical professionals have met Biogen’s marketing pitch with skepticism and outright denial.

140. An analysis of the clinical trial that serves as the basis for Biogen’s claims suggests that the actual improvement in gastric intolerance with Vumerity is likely minimal, if it exists at all. Vumerity’s purported average improvement was *one less day* of gastric upset. For MS patients who take these drugs over an extended time (as is typical) and for existing users of Tecfidera, there is no material difference.

141. Notably, the FDA-approved label for Vumerity does not include any claims of superiority of Vumerity over Tecfidera with respect to side effects or otherwise.

142. Instead, Vumerity is demonstrably *inferior* to Tecfidera. Switching from Tecfidera to Vumerity doubles the patient’s pill burden—the number of pills the patient must take every day. And a patient’s pill burden significantly affects the likelihood that she will adhere to the prescribed therapy. The fewer pills she must take, the more likely she is to adhere to the drug regimen, to avoid drug resistance, to have a better quality of life, and to have a better health outcome.

143. More than 25% of people with MS take five or more prescription medications. They often treat multiple symptoms with multiple medications which can lead to high medication or pill burden. Increasing the number of pills taken to treat the same symptoms does little to improve the treatment regimen for these patients. Failure to adhere to the therapy is associated with the development of drug resistance, toxicity, and lack of potency, among many other complications, including death.

144. Biogen's switching of the market from Tecfidera to Vumerity pushed patients in exactly the wrong direction in terms of pill burden, *doubling* the number of pills that patients are required to take. Vumerity was emphatically not a medical improvement over Tecfidera.

145. Biogen's own conduct confirms that conclusion. When it began selling Vumerity in October 2019, and continuing from that time to the present, Biogen sold Vumerity for *less than* Tecfidera. For example, in 2019 Biogen's list price for a day's supply of Tecfidera was \$249, versus \$228 for a day's supply of Vumerity. In 2021 the list prices were \$258 for Tecfidera, versus \$235 for Vumerity.

146. Biogen's promotional efforts in markets outside the United States further confirm that Vumerity is not a medical improvement over Tecfidera. In those non-U.S. markets, where Tecfidera still has patent protection, Biogen has continued to focus on promoting Tecfidera over Vumerity. In 2022, Biogen's Tecfidera sales outside the U.S. were more than \$1 billion, 32 times higher than its Vumerity sales of just \$32 million.

**B. Biogen Planned, but Failed, to Switch the Market to Vumerity Before Generic Tecfidera Entered the Market.**

147. As noted above (Section VI(a)), it was essential to Biogen's market-switch strategy that it move the prescription base from Tecfidera to Vumerity before generic Tecfidera became available.

**1. Biogen Readied Vumerity If It Lost the Patent Litigation.**

148. Biogen's patent protection was under attack on multiple fronts when Biogen filed for FDA approval of Vumerity in December 2018. Biogen sued several generic-drug manufacturers for infringement of U.S. Patent No. 8,399,514 ("514 Patent") because they had filed ANDAs seeking FDA approval of their generic Tecfidera products. The generic

manufacturers responded by alleging that Biogen's patent was invalid. If Biogen's '514 Patent had been upheld, it would not have expired until 2028.

149. One of the federal cases, between Biogen and Mylan Pharmaceuticals ("Mylan"), was pending in the Northern District of West Virginia. Biogen's other patent cases against generic manufacturers proceeded on a parallel track in the District of Delaware. Both cases were set for trial—one scheduled for December 2019 and the other for February 2020—when Biogen filed its NDA for Vumerity in December 2018.

150. In addition to the federal litigation, in February 2019, Mylan instituted an inter partes review ("IPR") challenge in the U.S. Patent and Trademark Office. Mylan's IPR proceeding also sought to invalidate the last remaining patent that protected Tecfidera, the '514 Patent.

151. Amid the uncertain climate of ongoing patent litigations for Tecfidera, Biogen told its investors that, if the Tecfidera patent was invalidated, it could switch the market to Vumerity. Biogen underscored this point, stating to investors that, "Importantly, ahead of the outcome of the IPR and District Court and the Litigations, we shall have the opportunity to launch VUMERITY, a novel oral fumarate disease-modifying treatment that has the potential to be another important choice for MS patients." Biogen explained that "[i]t is a priority that we appropriately maximize the potential of VUMERITY."

152. During that same investor call, an analyst asked, "Am I hearing it correct and also should we reasonably expect a meaningful switch ahead of IPR decision?" Biogen's CEO responded, "So from day one and this is the reason why we did the – we deployed capital and acquired this asset [the license from Alkermes] is that it was meaningful and strategically

important for the company.” He elaborated that “It would be premature to state on any clear tactical plan or strategy for launch. But while we speak, we are working thoroughly on that.”

153. A month later, the CEO again told investors that “obviously, the patent situation will certainly have an entrance into the tactical plan of launching VUMERITY. But for that, we are working hard and time will tell, okay? The important situation, again, is that VUMERITY will be launched months or quarters before the court ruling on the [Tecfidera] IP.”

154. Biogen later advised its investors that, “if we’re unsuccessful with either the two district court cases, we’ve got VUMERITY as a product that we can kind of look at, is a fumarate strategy that we’re looking at.”

## **2. Biogen’s Sole Motive Was to Impair Generic Tecfidera.**

155. Biogen’s sole motive in developing and marketing Vumerity was to use it in the evergreening strategy to defeat competition from generic Tecfidera. That exclusionary motive is confirmed by the fact that the strategy made economic sense for Biogen only because it had the effect of impairing generic competition. Biogen’s decision to incur the extra costs (and suffer the revenue losses) associated with switching the market from Tecfidera to Vumerity was economically rational only because the switch had the exclusionary effect of impairing generic competition. But for the impact on generic competition, Biogen would not have invested the resources necessary to reformulate and cannibalize Tecfidera because doing so would have been a money-losing proposition.

156. Biogen knew when it was planning the switch that its combined sales of Tecfidera and Vumerity would be far less than its sales of Tecfidera before the switch. And as events played out, Biogen’s forecast was correct.

157. But Biogen also knew that the combined sales of Tecfidera and Vumerity would be far greater than sales of Tecfidera alone following generic entry. The market switch would have the intended effect of shielding from generic competition all the prescriptions that Biogen managed to switch from Tecfidera to Vumerity before generic Tecfidera entered the market.

158. Biogen incurred very substantial costs to garner these reduced sales. Biogen spent significant sums to develop Vumerity, obtain a patent that purportedly protected it, gain FDA approval, promote the product, and make royalty payments to Alkermes. Under the terms of their operating agreement, FDA approval triggered a clause in which Biogen paid Alkermes \$150 million for the worldwide commercial rights to Vumerity, along with 15% royalties on all sales.

159. If the switch did not have the effect of impairing generic competition, the switch would have been a money-losing proposition for Biogen. The conduct made economic sense for Biogen solely because it did have the effect of impairing generic competition. Biogen's investments in reformulating and cannibalizing the sales of Tecfidera were not investments in improving products and helping patients; they were investments in impairing competition.

### **3. Biogen Botched the Timing of the Market Switch.**

160. Biogen knew that if it switched the prescription base to Vumerity before generic Tecfidera entered the market, doctors would not later switch them back to generic Tecfidera. Patients stay on a particular MS medication for long periods of time. Those patients like to stay on a drug once they find one that works. They do not want to risk unnecessary symptoms or complications by switching drugs.

161. Consequently, Biogen knew that if it switched the market before generic Tecfidera was available, the generics would make very few sales because, by that time, Biogen

would have all but eliminated the Tecfidera prescription base. Biogen would have deprived the generics of their only cost-efficient means of competing for sales.

162. The trouble for Biogen started with the outbreak of the COVID-19 pandemic in March 2020. Biogen's market-switch strategy relied on in-person sales pitches to the prescribing doctors. Given the minimal-to-non-existent clinical differences between Tecfidera and Vumerity, Biogen needed to rely on personal contacts with the doctors to convince them to switch.

163. Those in-person contacts became very difficult once COVID-19 hit. Biogen later reported to its investors that "it's important to note that the MS market in the US has been significantly impacted by lower new patient starts and switches due to COVID-19, as well as reduced engagement with physicians, which have both impacted the launch of VUMERITY."

164. Another problem arose when Biogen was unable to settle the patent lawsuits with the generic manufacturers. In July 2019, Biogen told its investors that "there was a lot of interest" in settling the patent litigations. Biogen anticipated that it could settle the patent litigations with agreements by the generic manufacturers to delay entering the market until years later. Biogen would use that delay to switch the market from Tecfidera to Vumerity.

165. Biogen's confidence that it could get delay through settlements was misplaced. It was unable to reach settlements with Mylan and other generic manufacturers before those cases went to trial. The bench trial in the Delaware case went forward in December 2019, and the bench trial in the West Virginia case proceeded in February 2020.

166. On June 18, 2020, the U.S. District Court for the Northern District of West Virginia found that Biogen's '514 patent was invalid. The District Court in Delaware reached the same conclusion on September 16, 2020.



167. After the first decision, in July 2020, Biogen advised investors that “[g]oing forward, our strategic focus is now on VUMERITY, and we are increasing our resource allocation to maximize this next-generation fumarate.” The CEO emphasized that “now the entire focus is pivoting on VUMERITY....” Biogen was making “a significantly enhanced focus of the organization on one brand, VUMERITY.”

168. Biogen’s Executive VP & Chief Medical Officer had told investors in 2019 that “physicians that I talked to would not want to switch somebody who’s done well who’s stabilized [after] the initial phases of taking TECFIDERA and are doing well in terms of tolerability.” But Biogen abruptly changed its position once competition from generic Tecfidera was imminent.

169. Biogen started using its army of sales force detailers to cannibalize the Tecfidera prescriptions, i.e., to aggressively switch them to Vumerity. Among many other marketing tactics, Biogen implemented “incentive schemes” for its salesforce, conditioning top pay to converting as many Tecfidera prescriptions as possible to Vumerity.

170. Beginning in late 2020, patient attempts to visit the Tecfidera webpage were automatically intercepted by a different webpage informing them of another option – Vumerity. From that page, patients could either choose to visit the Vumerity webpage or continue to the Tecfidera site.

Sponsored



vumerity.com  
<https://www.vumerity.com/>

VUMERITY® (diroximel fumarate) - Switching to VUMERITY®  
Visit The Site To Read About Switching To VUMERITY®, Including Info On Safety & Efficacy. Fill Out A VUMERITY® Start Form to Get Started Today. Three Steps To Starting Treatment.  
Important Safety Info. VUMERITY® Start Form.  
[Financial Support](#) · [Insurance & Copay Info](#) · [Additional Considerations](#) · [Consider Switching](#)

171. Even after losing both of the patent cases in the district courts, Biogen thought it still had time to switch the market to Vumerity before the entry of generic Tecfidera. When the brand drug has sales of the magnitude that Tecfidera achieved—more than \$3 billion annually—generic manufacturers will sometimes wait to enter the market despite a win in the district court. They wait until their trial-court victory is affirmed on appeal. If they enter the market and the patent victory is later overturned on appeal, they are liable to the brand manufacturer for patent infringement. On a drug like Tecfidera, the patent-infringement damages can be very substantial, and generic manufacturers are not always willing to take that kind of risk.

172. Accordingly, Biogen told its investors in July 2020—after Biogen’s first loss to a generic manufacturer at trial—that Biogen “assumed no generic entry for Tecfidera” in 2020. But Biogen’s planning was wrong again. Its patent was so weak that the generic manufacturers did not wait for an appellate decision affirming invalidation of the ’514 Patent before entering the market.

173. On August 17, 2020, the FDA approved Mylan’s ANDA for dimethyl fumarate. Mylan announced the launch of its generic Tecfidera capsules on August 19, 2020. Several additional generic competitors entered the market over the ensuing months.

174. Biogen's plan to switch the market to Vumerity before the generics entered the market was in shambles.

**IX. BIOGEN PAID THE PBMS TO IMPAIR COMPETITION FROM GENERIC TECFIDERA.**

175. Biogen's poor timing on the market switch prevented it from substantially impairing generic competition acting on its own. To achieve that anticompetitive goal, it had to enlist other industry participants—the PBMs.

176. Biogen had planned to impair generic competition by switching the market from Tecfidera to Vumerity before generic Tecfidera became available for sale. But COVID-19 made the switch more difficult, and generic Tecfidera became available much sooner than Biogen anticipated. So Biogen turned to a different plan. Even though generic Tecfidera was *available for sale*, Biogen paid the PBMs to ensure that it was *not in fact dispensed to patients*. Biogen used this period of impaired generic competition to switch as many prescriptions as possible from Tecfidera to Vumerity.

177. With the impending entry of generic Tecfidera, the PBMs finally had the opportunity to generate huge savings for the health plans and the insureds. The generics usually take 90% of the brand sales within 10 months of generic entry. And the generics sell at massive discounts off the brand price.

178. Instead, Biogen enlisted the PBMs in an anticompetitive scheme to thwart that robust competition. In July 2020 Biogen's CEO admitted that

since the focus now is on VUMERITY not on the fumarate, I can tell you that all levels [at Biogen] are aligned, at the payer level, at the patient services level, at the salesforce level -- including incentive schemes -- to shape their behavior, at the medical affairs level. So, the organization is absolutely aligned and focused on all of those levers.

As described below, Biogen pulled the “levers” by paying off the PBMs to help impede the generic competition that it was the PBMs’ job to promote.

**A. Biogen Paid Increased Rebates and Fees to PBMs for Impairing Generic Tecfidera.**

179. Biogen conditioned the PBMs’ receipt of additional rebates and fees on the PBMs’ refusing to promote generic Tecfidera on their formularies.

180. When generics became available, the PBMs had the unquestioned ability to drive the uptake of generic Tecfidera—or to impair and delay that uptake. Absent some anticompetitive purpose, PBMs promote the lower-price generic substitute for brand drugs. For example, CVS Health’s Form 10-K for 2023 states that the company “helps its PBM clients control costs by recommending plan designs that encourage the use of generic equivalents of brand name drugs when such equivalents are available.”

181. As noted above, the PBMs’ principal way to promote generics is to place them on the lowest (the best) tier on the formulary—Tier 1. Correspondingly, the PBMs place the counterpart brand drug on the highest (the worst) tier—Tier 5.

182. **Of course** a PBM that has not been paid off will promote the generic. Generics sell at a small fraction of the brand’s price. Here, within seven months of entering the market the generics were selling for \$17 per pill while brand Tecfidera was \$132 per pill.

183. Biogen paid each of the three PBMs (and others) to not promote or advantage generic Tecfidera over brand Tecfidera or Vumerity. It paid increased rebates and fees to PBMs if they agreed not to place the generics on a better tier than branded Tecfidera and Vumerity.

184. The PBMs passed *some* of the *rebates* on to *some* of their customers. They did not pass on any of the relevant unearned *fees*, which account for a substantial portion of the total kickbacks.

185. The PBMs are not buyers of Tecfidera, Vumerity or of the competing generic products. The PBMs are agents that negotiate formulary placement and prices on behalf of the health plans and the insureds. In paying the rebates and fees to the PBMs, Biogen was not competing with generic Tecfidera on price. It was paying agents—the PBMs—to impair that competition and thereby give Biogen time to conduct the market switch.

186. This is confirmed empirically by the basic economics. In 2022 the average acquisition cost for generic Tecfidera was just \$10 per pill—more than 93% off the list price of branded Tecfidera. In contrast, Biogen’s average rebates and fees (combined) on branded Tecfidera—even if they had been fully passed on by the PBMs to their health-plan clients—would have resulted in a net price just 28% off the list price. Biogen was not competing on price to win the health plans’ business. It was paying the health plans’ agents to undermine the generic competition that it was their job to promote.

187. The conclusion is no different when examining retail prices rather than acquisition cost. For example, in 2022 the typical retail price for generic Tecfidera was about \$25 per pill, versus an average net price—even if all rebates and fees had been passed on to the health plans—of \$100 per pill for brand Tecfidera. Notably, the average retail prices for generic Tecfidera were artificially increased by Biogen’s manipulation of the formularies. Pharmacies that sold generic Tecfidera outside the PBM ecosystem—pharmacies like Mark Cuban’s Cost Plus Drug Company—charged a retail price of only \$1 per pill.

188. Biogen’s rebates and fees were payments *to the PBMs* in exchange for impairing the generics, not price reductions to the health plans that, even if fully passed on to them, would have produced savings anywhere near what the generics offered. The rebates and fees were not

competitive price reductions to health plans; they were kickbacks to those plans' faithless agents in exchange for their help in impairing competition.

189. That conclusion is further reinforced by the change in the amount of rebates/fees that Biogen paid based on the *timing* of its market switch. Biogen paid the highest rebates/fees on Tecfidera in the key year 2021 as it worked feverishly to switch the market from Tecfidera to Vumerity. The average rebates/fees rose from 12% of the list price in 2019, to 19% in 2020 (the generics did not enter until Fall 2020), to the *high point of 45% in 2021*, and then declined to 28% in 2022, and 27% in 2023. Biogen was paying the PBMs for their help in making the market switch; it paid the highest rebates/fees in the year that it most needed their help to impair generic competition and make the switch.

190. Biogen was not paying these rebates/fees to win the health plans' business by competing with generic Tecfidera on price. If Biogen had been doing that, the list price of Tecfidera minus all rebates/fees would have been close to the price of generic Tecfidera and would have declined as the price of generic Tecfidera declined. That is not at all what happened.

191. Instead, the list price of Tecfidera minus all rebates/fees fell from \$115 per pill in 2019, to \$112 in 2020 (the generics did not enter until Fall 2020), to the *low point of \$75 in 2021*, and then *rose* substantially to \$100 in 2022, and \$110 in 2023. In contrast, the retail prices of generic Tecfidera were dramatically lower, and they substantially *and steadily* decreased over time. They did not, as Biogen's net prices did, increase after the critical year 2021. They continued to substantially decline.

192. If Biogen were competing on price for the health plans' business, it could have simply offered them a low net price. Biogen and the PBMs decided to use "rebates" and fees rather than low net prices to the health plans and insureds. And even if Biogen had some

unknown but legitimate reason to use rebates and fees rather than a low net price, it made the choice to pay the rebates and fees to the PBMs rather than to the health plans. Biogen paid rebates and fees to the PBMs because it was paying them off to help impair the generic competition that it was their proper role to promote.

193. And the PBMs knew that Biogen was using the competition-impaired time that it bought from them to switch the market from Tecfidera to Vumerity. The PBMs did not initially favor Vumerity over Tecfidera on their formularies. If Vumerity had medically significant advantages over Tecfidera, in terms of clinical effectiveness or patient tolerability, the PBMs would have placed Vumerity in a superior position on their formularies as soon as Vumerity was available. They did not.

194. The PBMs participated in the anticompetitive scheme and actively facilitated it because Biogen handsomely paid them to do so.

**B. Biogen's Scheme Caused PBMs to Designate Generic Tecfidera a Specialty Drug.**

195. Biogen's requirement that the PBMs not disadvantage brand Tecfidera or Vumerity compared to generic Tecfidera resulted in many of their formularies designating generic Tecfidera as a specialty drug.

196. Nothing about generic Tecfidera required special handling—it is a shelf-stable pharmaceutical dispensed in pill format. Nor did it carry a high price which sometimes results in PBMs designating a product a “specialty drug.” This was not a legitimate designation for generic Tecfidera.

197. Instead, the purpose and effect of Biogen's causing that designation was to make patients incur a very high copayment or coinsurance for generic Tecfidera, significantly reducing their incentive to accept the generic. Another purpose and effect was to require that the falsely

designated product be dispensed only through a small number of specialty pharmacies, shielding those pharmacies—owned by the PBMs—from price competition from all other pharmacies. Biogen knew and intended that this would substantially depress the sales of generic Tecfidera by keeping its price to health plans and other purchasers astronomically high.

198. The concentration and vertical integration in the PBM industry ensured that competition among the PBMs would not dissuade any one of them from designating generic Tecfidera as a specialty drug. All three are affiliated with a specialty pharmacy; all three shared a desire—absent effective competition among them—that its specialty pharmacy make these outlandish profits on the sale of generic Tecfidera; and each of the three knew that Biogen was offering the same kickbacks to the other two.

199. Indeed, the PBM-affiliated specialty pharmacies bought generic Tecfidera from the manufacturers for as little as \$180 for a 30-day supply; they sold it to the health plans and their insureds for as much as \$3,857.

200. The artificially high price that the PBM-affiliated specialty pharmacies charged to health plans for generic Tecfidera also had the intended effect of making the prices of branded Tecfidera and Vumerity appear to be more reasonable than they were. The artificially high price of the generic made the price of branded Tecfidera and Vumerity—plus some share of rebates—seem like a better deal than it really was for health plans and insureds.

201. If generic Tecfidera had been available to the health plans *at a competitive price*—for, say, \$3 per pill rather than the artificial \$64 per pill through the specialty pharmacy—health plans would have seen the prices of branded Tecfidera and Vumerity (even with some share of the rebates) as the rip-off that they were.



202. The artificially high price of generic Tecfidera through the specialty pharmacies had the effect that Biogen intended. It resulted in continued inflated sales of branded Tecfidera and Vumerity at supracompetitive prices. The PBMs went along with the anticompetitive scheme because Biogen paid them to.

**X. BIOGEN'S CORRUPT AGREEMENTS WITH THE PBMS SUPPRESSED GENERIC COMPETITION.**

203. Biogen's conduct had its intended effect of significantly impairing competition from generic Tecfidera.

**A. OptumRx's Formularies**

204. OptumRx serves as the PBM for UnitedHealth Group, Inc. ("UHG"), and it has been identified as one of UHG's "four reportable segments" (along with UnitedHealthcare, Optum Health, and Optum Insight). OptumRx's revenue contributes more than one third of UHG's overall revenues, which exceeded \$371 billion in 2023.

205. OptumRx manages approximately 22% of pharmacy benefit services in the U.S. and provides those services for over 66 million covered lives. It also operates a network of more than 67,000 pharmacies.

206. In 2023, OptumRx managed pharmaceutical spending of \$159 billion, which included \$63 billion in specialty pharmaceutical spending. OptumRx's revenue in 2023 exceeded \$116 billion.

207. In 2023 Optum Specialty Pharmacy earned \$32.3 billion in revenues from specialty pharmacy drugs. This represented 13% of prescription revenues from specialty pharmacy drugs in the U.S.

208. UHG offers a spectrum of products and services including health insurance plans through its wholly owned subsidiaries. UHG reported that it received from drug manufacturers

rebates of \$8.2 billion in 2022, and \$11 billion in 2023. It did not report the additional “fees” that it received, including those received by its offshore rebate aggregator, Emisar.

209. In exchange for the kickbacks from Biogen, OptumRx agreed not to advantage or promote generic Tecfidera on many of its formularies relative to Tecfidera or Vumerity. And this also caused OptumRx to designate generic Tecfidera as a specialty drug on many formularies.

210. As a consequence, in 2020 formularies governing more than 34% of OptumRx’s covered lives did not give generic Tecfidera any better treatment than Tecfidera or Vumerity on the formulary.<sup>1</sup> *In the key year of 2021 the number jumped to 49%.* Then it declined to “only” 37% in 2022 and 36% in 2023.

211. The kickbacks also caused very substantial numbers of health plans and insureds to pay “specialty drug” prices—as much as \$3,857 or more for a 30-day supply—for *generic* Tecfidera. For each year from 2020 through 2023, formularies governing at least 20% of OptumRx’s covered lives designated generic Tecfidera as a specialty drug.

212. Absent Biogen’s kickbacks, generic Tecfidera would have been treated like essentially all generic drugs that are not subject to anticompetitive pacts—it would have been placed on Tier 1 on all of OptumRx’s formularies. Instead, in 2020 formularies governing more than 41% of OptumRx’s covered lives did not have generic Tecfidera on Tier 1. *In the key year of 2021 that number jumped to 73%.* Then it declined to “only” 54% in 2022 and 57% in 2023.

213. Just like the data regarding rebates/fees, the magnitude of these percentages and their pattern confirm Biogen’s scheme to pay off the PBMs to enable the market switch from

---

<sup>1</sup> Managed Markets Insight & Technology, LLC, is the source for many of the formulary data summaries alleged herein.

Tecfidera to Vumerity. Biogen succeeded in coopting OptumRx to enable the market switch in the key year 2021.

**B. CVS Caremark's Formularies**

214. CVS Caremark manages approximately 34% of pharmacy benefit services in the U.S. and provides those services for approximately 108 million covered lives. CVS Caremark operates the largest chain of retail pharmacies in the country, with more than 9,000 locations.

215. In 2023 CVS Specialty's revenues were \$73.3 billion from sales of specialty drugs. This represented 30% of prescription revenues from all specialty drugs nationwide.

216. In 2018, CVS Health Corp., acquired Aetna for \$69 billion and became the first combination of a major health insurer, PBM, and mail-order and retail pharmacy chain. As a result, CVS Health Corp. controls the health plan/insurer and PBM services provided to Aetna, the third largest health insurer in the U.S. In 2023, Aetna reported revenue of approximately \$105.6 billion. It offers medical, pharmacy, and other insurance plans in the commercial, Medicare Advantage, and Managed Medicaid markets.

217. In exchange for the kickbacks from Biogen, CVS Caremark agreed not to advantage generic Tecfidera on many of its formularies relative to Tecfidera or Vumerity. And this also caused CVS Caremark to designate generic Tecfidera as a specialty drug on many formularies.

218. As a consequence, in 2020 formularies governing more than 21% of CVS Caremark's covered lives did not give generic Tecfidera any better treatment than Tecfidera or Vumerity on the formulary. In the key year of 2021 the number nearly doubled, to 38%. The number was 36% in 2022 and 39% in 2023.

219. The kickbacks also caused very substantial numbers of health plans and insureds to pay "specialty drug" prices—as much as \$3,857 or more—for *generic* Tecfidera. In 2020

formularies governing 11% of CVS Caremark's covered lives designated generic Tecfidera as a specialty drug. In the key year 2021 that number almost doubled, to 20%. It was 18% in 2022, and 19% in 2023.

220. Absent Biogen's kickbacks, generic Tecfidera would have been treated like essentially all generic drugs that are not subject to anticompetitive pacts—it would have been placed on Tier 1 on all of CVS Caremark's formularies. Instead, in 2020 formularies governing more than 41% of CVS Caremark's covered lives did not have generic Tecfidera on Tier 1. In the key year of 2021 that number jumped to 49%. It was 47% in 2022 and in 2023.

### **C. Express Scripts' Formularies**

221. Express Scripts manages approximately 23% of pharmacy benefit services in the U.S. and provides those services for more than 100 million covered lives.

222. Cigna, which merged with Evernorth in 2018, is the fourth largest health insurer in the U.S. It offers commercial and Medicare Advantage medical, pharmacy and other insurance plans. As a result, the Evernorth corporate family controls the health plan/insurer, the PBM, and the mail order pharmacies used by approximately 15 million Cigna members in the U.S.

223. Evernorth reported to its shareholders that it “operates various group purchasing organizations that negotiate pricing for the purchase of pharmaceuticals and formulary rebates with pharmaceutical manufacturers on behalf of their participants” and operates the company's Pharmacy Rebate Program while ESI provides formulary management services. In 2021, Evernorth reported adjusted revenues of \$131.9 billion (representing 75.8% of the Cigna's revenues), which was up from \$116.1 billion in 2020. In 2023 Evernorth reported its adjusted revenues as exceeding \$153 billion.

224. Express Scripts' specialty pharmacy, Accredo, earned \$59.5 billion in revenues in 2023. This was a 24% share of prescription revenues from all specialty pharmacy drugs nationwide.

225. In exchange for the kickbacks from Biogen, Express Scripts agreed not to advantage generic Tecfidera on many of its formularies relative to Tecfidera or Vumerity. And this also caused Express Scripts to designate generic Tecfidera as a specialty drug on many formularies.

226. As a consequence, in 2020 formularies governing more than 24% of Express Scripts' covered lives did not give generic Tecfidera any better treatment than Tecfidera or Vumerity on the formulary. In the key year of 2021 the number rose to 34%. The number then declined to 14% in 2022 and in 2023.

227. The kickbacks also caused very substantial numbers of health plans and insureds to pay "specialty drug" prices—as much as \$3,857 or more—for *generic* Tecfidera. In 2020 formularies governing 5% of Express Scripts' covered lives designated generic Tecfidera as a specialty drug. In the key year 2021 that number tripled, to 15%. It was 12% in 2022 and in 2023.

228. Absent Biogen's kickbacks, generic Tecfidera would have been treated like essentially all generic drugs that are not subject to anticompetitive pacts—it would have been placed on Tier 1 on all of Express Scripts' formularies. Instead, in 2020 formularies governing more than 29% of Express Scripts' covered lives did not have generic Tecfidera on Tier 1. In the key year of 2021 that number jumped to 36%. It then declined to 19% in 2022 and in 2023.

#### **D. The Cumulative Numbers**

229. The three PBMs manage the pharmacy benefits for approximately 80% of all patients in the U.S. But Biogen made the same corrupt bargain with other major PBMs too.

230. All told, in the key year 2021 more than 45% of the 300 million Americans with pharmacy benefit coverage were covered by formularies that did not give generic Tecfidera any better tier placement than Tecfidera or Vumerity. In that year, 17%—52 million people—were subjected to formularies that designated generic Tecfidera as a “specialty” drug. And 54%—164 million Americans—were governed by formularies that did not place generic Tecfidera on Tier 1.

231. The reality was (and is) even worse than these numbers imply. In paying the PBMs to impair generic competition, Biogen achieved an anticompetitive effect even beyond the significant harm implied by simply adding up the individual numbers.

232. When formularies that govern a significant portion of prescriptions restrict access to a less expensive generic like dimethyl fumarate, that limited access has a negative *spillover effect* at the prescriber level.

233. A doctor who repeatedly encounters difficulty prescribing a certain medication (because it is not preferred by a PBM) is less likely to prescribe that product to other patients in the future, including patients who are not members of the same health plan. A doctor’s patients are covered by many different health plans, and each health plan covers different products. Instead of researching each patient’s coverage before prescribing a product, doctors tend to default to the product they know is preferred on most formularies. The aggregate effect is that if a given product is not preferred on a substantial number of formularies, doctors will tend to prescribe a product that is preferred.

234. Accordingly, the intended effect of Biogen’s impairing generic Tecfidera on many formularies was that doctors were much more likely to prescribe Vumerity. They did so

even for patients whose health plans did not disadvantage the generics. And the formularies that did prefer generic Tecfidera were less able to drive sales toward the generics.

235. This spillover effect from Biogen's unlawful payments made their anticompetitive conduct even worse than it appears when measured only by covered lives under the formularies as to which Biogen paid the kickbacks.

**E. The Resulting Massive Increases in Biogen's Branded Sales.**

236. Biogen's payoffs to the PBMs worked. In June 2020, before the courts invalidated Biogen's patent and it started switching the market in earnest, Vumerity had monthly unit sales of just 50,000. With the PBMs' substantial help in impairing generic competition, by June 2021 Vumerity's monthly unit sales had rocketed to more than 423,000. Almost all of those sales came from prescriptions that would have been for Tecfidera and substituted with the generic.

237. Had Biogen not paid the PBMs to enable the market switch from Tecfidera to Vumerity, by June 2021, 90% or more of the relevant prescriptions would have been filled with generic Tecfidera. That is the typical sales-erosion rate for branded prescription-drug pills. The significant erosion of sales of branded Tecfidera would have, in turn, dramatically limited the Tecfidera prescription base available for Biogen's sales force to switch to Vumerity.

238. Instead, Biogen's payoffs to the PBMs prevented generic Tecfidera from taking the typical 90% of sales. Due to Biogen's unlawful conduct, in that timeframe generic Tecfidera was able to take *less than a third* of the combined Tecfidera and Vumerity sales.

239. Thus, just as Biogen intended, its unlawful conduct significantly: (a) slowed the erosion of Tecfidera sales; and (b) artificially inflated the number of prescriptions for Vumerity. Those sales of branded Tecfidera and Vumerity came at the expense of the dramatically less expensive generic Tecfidera.

240. That conclusion is confirmed by focusing on the timeline for sales of Vumerity. Based on Vumerity's medical merit—that is, its *lack* of substantial improvement over Tecfidera—without Biogen's payoffs Vumerity would have achieved unit sales of less than 5% of the monthly unit sales that branded Tecfidera had in July 2020.


241. That very modest sales figure for Vumerity is readily confirmed. First, Biogen's own clinical studies show that, at most, only about 4% of patients benefit from taking Vumerity rather than Tecfidera over a five-week period. And, as noted above, medical professionals have doubted even that purported small benefit.

242. Second, before Biogen began paying the PBMs, Vumerity had been on the market for more than eight months but had achieved monthly unit sales of only 50,225 capsules (equal to only 419 thirty-day supplies at four capsules per day). That was just 2% compared to Tecfidera's sales of 2,495,616 capsules (equal to 41,594 thirty-day supplies at two capsules per day), and only 1.0% when measured in standardized 30-day supplies.


243. Just as Biogen intended, its unlawful conduct significantly and artificially inflated the sales of both Tecfidera and Vumerity. Those sales came at the expense of the dramatically less expensive generic Tecfidera.

244. Absent Biogen's unlawful conduct, its combined unit sales of branded Tecfidera and Vumerity, compared to sales of generic Tecfidera, would have looked approximately like this:





245. As a result of Biogen's payoffs to the PBMs, its actual combined unit sales of branded Tecfidera and Vumerity during that same timeframe, compared to sales of generic Tecfidera, looked approximately like this:



246. To overcome the price disconnect in pharmaceutical markets, Congress and every State promote the distribution of generic drugs through automatic substitution at the pharmacy counter. That automatic substitution is generic manufacturers' cost-efficient means of competing. Biogen's payoff-enabled market switch substantially impaired generic manufacturers' cost-efficient means of competing, and deprived health plans and insureds of the benefits of that competition.

247. Biogen's market switch substantially foreclosed generic competition by denying generic manufacturers a fair opportunity to compete using state generic-substitution laws. Biogen's kickback-enabled campaign to switch patients to Vumerity effectively coerced patients

and Class members to purchase brand Tecfidera and Vumerity despite the availability of more affordable generic Tecfidera.

248. Only brand manufacturers—not generic manufacturers—pay rebates and fees to PBMs. So the PBMs shared Biogen’s goal of seeing as many prescriptions as possible switched from Tecfidera to Vumerity, not to the generic. The PBMs will go on collecting rebates on Vumerity into the future—the patents on Vumerity do not expire until 2033.

249. Manufacturers do not pay any rebates or fees to PBMs on generic Tecfidera. The economic benefits of generic Tecfidera flow to actual drug purchasers, not to their faithless agents, the PBMs.

250. Biogen’s impairment of competition from generic Tecfidera during the period August 2020 to April 2024 cost purchasers more than \$3 billion in lost savings. Biogen’s anticompetitive conduct prevented purchasers from substituting generic Tecfidera for branded Tecfidera, and permitted Biogen to switch a substantial portion of the market from Tecfidera to Vumerity, for which generic Tecfidera is not substitutable under state substitution laws.

251. Those losses continue to pile up, and will go on piling up absent effective injunctive relief from this Court. As of May 2024, Vumerity has a sales base of more than a million units per month. No generic is available for that product. Absent Biogen’s unlawful conduct, Vumerity would have a prescription base of less than 200,000 units per month.

252. Bottom line: health plans and insureds are paying for the difference. They are paying for more than 800,000 units per month for branded Vumerity that, absent Biogen’s unlawful conduct, would have been filled with generic Tecfidera. The difference in cost for the brand Vumerity versus generic Tecfidera for those prescriptions is a staggering \$655 million per year. Absent effective injunctive relief, those overcharges could continue until 2033.

253. Those two elements of loss—the initial overcharges of more than \$3 billion for the period August 2020 to April 2024, and the ongoing overcharges of \$655 million per year—do not exhaust the losses. The economic losses from designating generic Tecfidera as a specialty drug are not included in those amounts. The specialty drug part of the scam has already cost health plans an estimated additional \$500 million. Those losses, too, are continuing.

## **XI. THE SCHEME’S ANTICOMPETITIVE EFFECTS**

254. Biogen’s scheme and payments to suppress generic competition to Tecfidera have delayed and substantially diminished the sale of generic Tecfidera. By delaying the onset of full generic competition and decimating the prescription base, Biogen deprived would-be generic manufacturers of the most efficient means of distribution under the governing statutes and regulations.

255. Biogen’s anticompetitive conduct, and the PBMs’ participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell Tecfidera and Vumerity at artificially inflated units and prices. But for Biogen’s illegal conduct, generic manufacturers would have been able to enter the market unimpeded and compete on the merits against Tecfidera and Vumerity. Biogen’s conduct unlawfully prevented purchasers of Tecfidera and Vumerity from obtaining the benefits of unimpaired generic competition.

256. Biogen’s scheme and unlawful payments harmed Plaintiffs and the Class by depriving them of a market in which: (1) the prescription base available for automatic generic substitution is determined by unrestrained competition; (2) they receive the honest services of PBMs, untainted by kickbacks for promoting higher-priced branded drugs rather than generics; (3) generic drug manufacturers have unimpaired access to the most cost efficient means of

distribution; and (4) follow-on branded products must compete on the merits, unaided by kickbacks that enable and facilitate a market switch designed to impair generic competition.

257. But for Biogen's unlawful conduct: (1) by June 2021 about 90% of prescriptions for Tecfidera would have been filled with the much less expensive generic Tecfidera; and (2) Biogen would have been able to switch few Tecfidera prescriptions to Vumerity.

258. Biogen's unlawful conduct has delayed and diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell Tecfidera and Vumerity at artificially inflated, supracompetitive prices. As a consequence, Plaintiffs and other Class members have sustained substantial losses and damage to their business and property in the form of overcharges, the exact amount of which will be the subject of proof at trial.

## **XII. CLASS ACTION ALLEGATIONS**

259. Plaintiffs bring this action on behalf of itself and, under Fed. R. Civ. P. 23(a), 23(b)(2), and (b)(3), as representative of a Class defined as follows:

All entities that purchased, paid and/or provided reimbursement for some or all of the purchase price of Vumerity, Tecfidera, and/or its AB-rated generic equivalents in any form, in the United States and its territories, for consumption by their members, insureds, or beneficiaries (the "Class"), other than for resale, during the period August 19, 2020 through and until the anticompetitive effects of Biogen's unlawful conduct cease (the "Class Period").

260. The following persons or entities are excluded from the proposed Class:

- a. Defendant and its co-conspirators named herein, and their management, subsidiaries, or affiliates; and
- b. All federal or state governmental entities.

261. Class members are so numerous that joinder is impracticable. Plaintiffs believe that the Class includes thousands of third-party payors.

262. Plaintiffs' claims are typical of those of the Class members. Plaintiffs and all Class members were damaged by the same wrongful conduct of Biogen, i.e., they paid artificially inflated prices for Tecfidera and Vumerity and were deprived of the benefits of more robust competition from cheaper generic versions of Tecfidera as a result of Biogen's wrongful conduct.

263. Plaintiffs will fairly and adequately protect and represent the interests of the Class. Plaintiffs' interests are coincident with, and not antagonistic to, those of the Class.

264. Plaintiffs are represented by counsel with experience in the prosecuting class action antitrust litigation, and with particular experience in class action antitrust litigation involving pharmaceutical products.

265. Questions of law and fact common to the Class members predominate over questions that may affect only individual Class members because Biogen has acted on grounds generally applicable to the entire Class, thereby making overcharge damages with respect to the Class as a whole appropriate. Such generally applicable conduct is inherent in Biogen's wrongful conduct.

266. Questions of law and fact common to the Class include, but are not limited to:

- a. whether Biogen conspired to suppress generic competition to Tecfidera;
- b. whether Biogen and one or more of the three PBMs entered into an unlawful agreement in restraint of trade;
- c. whether, pursuant to the agreement, one or more of the PBMs agreed to disfavor generic Tecfidera on its formularies;
- d. whether, pursuant to the agreement, Biogen compensated the PBM;
- e. whether Biogen's compensation to the PBM was necessary to yield some procompetitive benefit that is cognizable and non-pretextual;
- f. whether the agreement is illegal under the rule of reason;

- g. whether Biogen switched the market from Tecfidera to Vumerity in order to impair competition from generic Tecfidera;
- h. whether the law requires definition of a relevant market when direct proof of market power is available and, if so, the definition of the relevant market;
- i. whether Biogen's conduct as alleged herein has substantially affected interstate commerce;
- j. whether, and to what extent, Biogen's conduct caused antitrust injury (i.e., overcharges) to Plaintiffs and the Class members; and
- k. the quantum of aggregate overcharge damages to the Class.

267. Class action treatment is a superior method for the fair and efficient adjudication of the controversy. Such treatment will permit a large number of similarly situated persons to prosecute their common claims in a single forum simultaneously, efficiently, and without the unnecessary duplication of evidence, effort, or expense that numerous individual actions would engender. The benefits of proceeding through the class mechanism, including providing injured persons or entities a method for obtaining redress on claims that could not practicably be pursued individually, substantially outweigh potential difficulties in management of this class action.

268. Biogen's anticompetitive conduct has imposed and will continue to impose (unless the Court grants effective equitable relief) a common antitrust injury on Plaintiffs and all Class members. Biogen's anticompetitive conduct and its relationships with the Class members have been substantially uniform. Biogen has acted and refused to act on grounds that apply to the class generally, and injunctive and other equitable relief is appropriate respecting the class as a whole.

269. Plaintiffs know of no special difficulty to be encountered in the maintenance of this action that would preclude its maintenance as a class action.

### **XIII. INTERSTATE AND INTRASTATE COMMERCE**

270. At all material times, Biogen manufactured, marketed, promoted, distributed, and sold substantial amounts of Tecfidera and Vumerity in a continuous and uninterrupted flow of commerce across state and national lines and throughout the United States.

271. At all material times, Biogen transmitted funds, as well as contracts, invoices, and other forms of business communications and transactions, in a continuous and uninterrupted flow of commerce across state and national lines in connection with the sale of Tecfidera and Vumerity and/or their AB-rated bioequivalents.

272. In furtherance of its efforts to restrain competition with respect to Tecfidera and Vumerity, Biogen employed the United States mail and interstate and international telephone lines, as well as means of interstate and international travel. Biogen's activities were within the flow of and have substantially affected interstate commerce.

273. Biogen's anticompetitive conduct has substantial intrastate effects in that, among other things, purchasers within each state were impaired in buying less expensive generic Tecfidera within the state. The impairment of competition from generic Tecfidera directly impacts and disrupts commerce for purchases and sales within each state.

274. Biogen produces, manufactures, distributes, and sells Tecfidera and Vumerity throughout the United States through means of interstate commerce. Biogen sold and shipped substantial quantities of Tecfidera and Vumerity in a continuous and uninterrupted flow in interstate commerce to customers located throughout the United States. The PBMs placed Tecfidera and Vumerity on their formularies in interstate commerce and sold Tecfidera and Vumerity, directly and/or through their affiliated specialty pharmacies, in interstate commerce.



275. Biogen's business activities at issue in this Complaint were within the flow of, and substantially affected, interstate trade and commerce, as commerce is defined in Section 1 of the Clayton Act, 15 U.S.C. § 12(a).

#### **XIV. MARKET POWER AND MARKET DEFINITION**

276. Biogen had the ability to control the prices of fumarate and exclude relevant competitors. Direct evidence of Biogen's market power includes the following: (a) from 2013 through the present Biogen's per-unit manufacturing cost for fumarate has been less than 15% of the net price of the drug, *i.e.*, the price after adjusting for rebates and discounts; (b) Biogen never lowered the price of fumarate to the competitive level in response to pricing of other brand or generic drugs; and (c) from launch in April 2013 to June 2020, Biogen profitably raised the price of Tecfidera by approximately 79%. During that period, the Consumer Price rose by only 10.7%.

277. To the extent that Plaintiffs are required to prove market power by defining a relevant product market, Plaintiffs allege that, for the purpose of evaluating the competitive effect of Biogen's conduct, the relevant product market is the market for Tecfidera, Vumerity, and their AB-rated generic equivalents (collectively, "fumarate") and narrower markets therein. At all relevant times, Biogen had market power in the fumarate market because it had the power to raise or maintain the price of fumarate at supracompetitive levels without losing enough sales to make supracompetitive prices unprofitable.

278. A small but significant, non-transitory increase in the competitive price of fumarate did not cause a significant loss of sales. At competitive prices, Biogen's fumarate does not exhibit significant, positive, cross-elasticity of demand with respect to price with any MS drug other than AB-rated generic Tecfidera.

279. Biogen needed to control only fumarate, and no other products, in order to maintain the price of the fumarate products profitably at supracompetitive prices. Only the

unimpaired market entry of a competing, AB-rated generic version of Tecfidera would render Biogen unable to profitably maintain supracompetitive prices for those products.

280. Doctors generally select MS drugs for their patients based on the clinical and pharmacological attributes of the drug and the patients' relevant characteristics, rather than principally on price. For clinical reasons, among others, physicians and patients prefer fumarate to other MS drugs for certain patients. Due to, among other reasons, its use and effectiveness in reducing MS relapses, delaying the progression of physical disability associated with MS, and slowing the development of MS-related brain lesions fumarate is significantly differentiated from all products other than AB-rated generic Tecfidera.

281. Fumarate's medical and clinical attributes significantly differentiate it from other MS drugs. Other MS drugs have different chemical compounds and formulations, and the FDA does not consider them to be interchangeable with fumarate.

282. Fumarate is the most frequently prescribed oral MS drug in the world. Most other pharmaceutical treatment options require intravenous infusions—Natalizumab (Tysabri) and Ocrelizumab (Ocrevus)—or injections—Interferon beta-1a (Avonex), Interferon beta-1b (Betaseron), and Glatiramer acetate (Copaxone). And all of these IV infusions and injectables have much worse side-effect profiles than fumarate. These include skin reactions or infection at the infusion or injection site, fatigue, muscle weakness, flu-like symptoms, headache, fever, nausea, and joint pain.

283. Teriflunomide (Aubagio) is an orally administered MS drug, but it causes diarrhea, nausea, hair loss, and liver problems. In contrast, the most common side effects for fumarate are flushing and gastrointestinal upset. Those side effects are easily mitigated by taking the medication with food or aspirin.

284. Biogen advised its investors in April 2020 that the entry of another MS drug pill, Banner's Bafiertam, would not "significant[ly] impact" Tecfidera's sales. Bafiertam is monomethyl fumarate, which produces the same active metabolite as Tecfidera. Biogen explained that despite the chemical similarities, Bafiertam would not significantly affect Tecfidera's sales because Bafiertam "is not a directly substitutable A/B product."

285. Biogen's statement proved to be accurate. As of May 2024, Bafiertam sells only approximately 46,000 capsules per month (383 thirty-day supplies at 4 capsules per day). Less than 2% of the combined dimethyl, monomethyl, and diroximel fumarate unit sales are of Bafiertam.

286. At all relevant times, Biogen enjoyed high barriers to entry with respect to the above-defined relevant market due to patent protection, the high cost of entry and expansion, expenditures in marketing and physician detailing, and AB-rated generic substitution laws.

287. Until July 2020, Biogen's market share in the relevant market was 100%. From July 2020 through the present its dollar share of the market has exceeded 85%, and its unit share has been as high as 95% and has always exceeded 45%. Biogen's anticompetitive conduct has shielded approximately 800,000 monthly unit sales of fumarate from generic competition.

288. The United States and its territories constitute the relevant geographic market.

289. Biogen's market power with respect to fumarate was substantial—it was monopoly power.

## **XV. MARKET EFFECTS AND DAMAGES TO THE CLASS**

290. Biogen's anticompetitive conduct had the purpose and effect of restraining competition unreasonably and injuring competition by protecting its fumarate products from

generic competition. That conduct has caused Plaintiffs and the Class to pay more than they would have paid for fumarate absent Biogen's illegal conduct.

291. Typically, generic versions of brand drugs are initially priced significantly below the corresponding brand drug to which they are AB-rated. As a result, upon generic entry, health plans and insureds rapidly substitute generic versions of the drug for some or all of their purchases. As more generic manufacturers enter the market, prices for generic versions of a drug predictably plunge even further due to competition among the generic manufacturers, and, correspondingly, the brand drug loses even more of its market share to the generic versions of the drug. This price competition enables all purchasers of the drug to: (a) purchase generic versions of a drug at substantially lower prices, and/or (b) purchase the brand drug at a reduced price. Consequently, brand manufacturers have a keen financial interest in impairing generic competition, and purchasers experience substantial cost inflation from that impairment.

292. But for Biogen's anticompetitive conduct, Plaintiffs and Class members would have paid less for fumarate because, among other reasons, they would have: (a) substituted more purchases of less-expensive AB-rated generic Tecfidera for their purchases of more-expensive branded Tecfidera; (b) received lower prices for their few purchases of branded Tecfidera; (c) substituted more purchases of less-expensive AB-rated generic Tecfidera for the prescriptions that Biogen switched from Tecfidera to Vumerity; (d) paid far less for their purchases of AB-rated generic Tecfidera; and (e) paid less for their few purchases of Vumerity.

293. During the Class Period, Plaintiffs and other Class members purchased substantial amounts of Biogen's fumarate. As a result of Biogen's illegal conduct, Plaintiffs and other Class members were compelled to pay, and did pay, artificially inflated prices for Biogen's fumarate drugs. Plaintiffs and the other Class members paid prices for Biogen's fumarate that were

substantially greater than the prices that they would have paid absent the illegal conduct alleged herein, because they: (1) were deprived of the opportunity to purchase lower-priced generic Tecfidera instead of expensive brand Tecfidera and/or brand Vumerity; (2) paid artificially inflated prices for Tecfidera and Vumerity; and (c) paid artificially inflated prices for generic Tecfidera.

294. As a consequence, Plaintiffs and other Class members have sustained substantial losses and damage to their business and property in the form of overcharges, the exact amount of which will be the subject of proof at trial.

## **XVI. ANTITRUST IMPACT**

295. During the relevant period, Plaintiffs and Class members purchased substantial amounts of Tecfidera, generic Tecfidera and/or Vumerity directly from Biogen or its Co-Conspirator specialty pharmacies and/or indirectly from others, other than for resale. As a result of Biogen's illegal conduct, Plaintiffs and Class members were compelled to pay, and did pay, artificially inflated prices for their fumarate requirements.

296. Overcharges at a higher level of distribution generally result in higher prices at every level below. Wholesalers and retailers passed on the inflated prices of fumarate drugs to Plaintiffs and Class members, and the Co-Conspirator specialty pharmacies directly charged inflated prices to Plaintiffs and Class members.

297. Biogen's anticompetitive conduct allowed it to charge health plans and insureds prices in excess of what Biogen otherwise would have been able to charge absent Biogen's anticompetitive conduct. Another purpose and effect of Biogen's anticompetitive conduct was to enable the PBM-affiliated co-conspirator specialty pharmacies to charge health plans and insureds prices in excess of what those pharmacies otherwise would have been able to charge.

298. The prices were inflated as a direct, foreseeable, and intended result of Biogen's anticompetitive conduct. The inflated prices that Plaintiffs and Class members paid are traceable to, and the foreseeable result of, the overcharges that Biogen's conduct caused.

299. Biogen's unlawful conduct deprived Plaintiffs and the Class of the benefits of competition that the antitrust laws were designed to ensure, and their injuries flow from that which makes Biogen's conduct unlawful.

## **XVII. COMPLIANCE WITH NOTICE AND DEMAND REQUIREMENTS**

300. In accordance with the requirements of Arizona Revised Statute § 44-1415; Conn. Gen. Stat. Ann. § 35-37; Mass. Gen. Laws Ann. ch. 93A, § 10; Minn. Stat. § 325D.63; Nevada Revised Statute § 598A.210(3); Or. Rev. Stat. § 646.780(5)(b); Rhode Island General Laws § 6-36-21; and Utah Code § 76-10-3109, on or about August 16, 2024, September 20, 25 and 26, 2024, counsel for Plaintiffs sent letters regarding this class-action litigation to the Attorneys General of Arizona, Connecticut, Massachusetts, Minnesota, Nevada, Oregon, Rhode Island, and Utah. The letters informed the Attorneys General of the existence of Plaintiffs' lawsuits, identified the relevant state antitrust provisions at issue, and enclosed a copy of their initial complaints.

301. On or about August 15, 2024, September 20, 25, and 27, 2024, counsel for Plaintiffs sent demand letters to Biogen regarding this class-action litigation, which satisfy the demand-letter requirements of certain consumer-protection statutes mentioned below (e.g., Massachusetts). The demand letters identified the claimants as Plaintiffs, in their individual and representative capacity; described the allegedly unfair or deceptive acts or practices that Biogen committed (i.e., its efforts to suppress competition from generic Tecfidera); described Plaintiffs' and Class members' injury (increased prices for fumarate); set forth a demand for relief (treble

damages, attorneys' fees, litigation costs, and other available sanctions); and requested an offer to cure within the statutorily prescribed time.

## **XVIII. CLAIMS FOR RELIEF**

### **CLAIM ONE VIOLATION OF 15 U.S.C. § 1 CONTRACT IN RESTRAINT OF TRADE**

302. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

303. At all relevant times, Biogen possessed market power in the relevant market. Biogen possessed the power to raise and maintain supracompetitive prices and exclude competitors from the relevant market.

304. Biogen entered into agreements with each of the three PBMs pursuant to which it agreed to pay, and did pay, substantial kickbacks to each of them in exchange for their reciprocal agreement to disadvantage generic Tecfidera on their formularies and/or to designate generic Tecfidera as a specialty drug. Biogen made each of the agreements with the purpose and effect of impairing generic competition to buy time for Biogen to switch the market from Tecfidera to Vumerity.

305. The purpose and effect of the payments that Biogen made to the three PBMs under the agreements was to substantially impair competition from generic Tecfidera. There is and was no legitimate, non-pretextual, procompetitive business justification for the payments and restrictions on competition that outweighs the harmful effects of the payments and restrictions on competition. Even if there were some such conceivable justification, the payments were not necessary to achieve such a purpose.

306. The agreements, individually and collectively, covered a sufficiently substantial percentage of the relevant commerce to harm competition.

307. As a direct and proximate result of Biogen's unlawful restraint of trade, Plaintiffs and Class members paid artificially inflated prices for fumarate and were harmed as a result.

308. Plaintiffs and Class members have been injured in their business or property by reason of Biogen's antitrust violations. These injuries are of the type that the Sherman Antitrust Act, 15 U.S.C. § 1, was designed to prevent, and flow from that which makes Biogen's conduct unlawful.

309. Plaintiffs and Class members seek damages, treble damages, and injunctive relief as permitted by law for the injuries they suffered as a result of Biogen's anticompetitive conduct.

**CLAIM TWO**  
**VIOLATION OF 15 U.S.C. § 2**  
**CONSPIRACY TO MONOPOLIZE**

310. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

311. At all relevant times, Biogen possessed substantial market power (i.e. monopoly power) in the relevant market. Biogen possessed the power to raise and maintain supracompetitive prices and exclude competitors from the relevant market.

312. Biogen conspired with the PBMs and their specialty pharmacies to create and maintain a monopoly in the market for fumarate. Biogen and the PBMs and specialty pharmacies' engaged in anticompetitive conduct in furtherance of the conspiracy to maintain its monopoly, which included, cumulatively and in the alternative: (a) agreeing to pay and paying one or more of the three PBMs to disadvantage generic Tecfidera on their formularies; (b) agreeing to pay and paying one or more of the three PBMs with the purpose and effect of causing



them to designate generic Tecfidera as a specialty drug; (c) making those payments knowing that the PBMs owed a fiduciary duty to their health-plan clients and that they hid some or all of the payments from their clients and funneled some or all of the payments to offshore affiliates; (d) engaging in this conduct in order to switch the market from Tecfidera to Vumerity; (e) entering into agreements that caused Plaintiffs and Class members to be required to purchase Tecfidera, Vumerity and generic Tecfidera from the PBM-owned specialty pharmacies at supracompetitive prices; and (f) conspiring to impair generic competition and suppress sales of lower cost generic Tecfidera.

313. Through Biogen's conspiracy to monopolize, Biogen willfully maintained and continues to maintain monopoly power in the relevant market using restrictive and exclusionary conduct, rather than by providing better products or services, and thereby injured the Plaintiffs and Class members.

314. The goal, purpose and effect of the Biogen-directed conspiracy was and is to maintain and extend Biogen's monopoly over the relevant market by and through the anticompetitive conduct in furtherance of the conspiracy described above.

315. Biogen's conspiracy to monopolize harmed competition and purchasers as alleged above.

316. There are no non-pretextual procompetitive justifications for Biogen's conspiracy to monopolize. Even if there were such a conceivable justification, the conspiracy's anticompetitive effects far outweigh any conceivable justification. Further, the conspiracy to monopolize was far broader than necessary to achieve any conceivable procompetitive benefit.

317. Biogen's conspiracy to monopolize was the direct and proximate cause of the injuries to Plaintiffs and Class members.

318. Plaintiffs and the Class members have been injured in their business or property as a direct and proximate result of Biogen's conspiracy to monopolize, and their injuries are the type that the Sherman Antitrust Act, 15 U.S.C. § 2, was designed to prevent, and flow from that which makes Biogen's conduct unlawful.

319. By engaging in the foregoing anticompetitive conduct, Biogen has intentionally and wrongfully conspired to monopolize in violation of the Sherman Act.

320. Plaintiffs and Class members seek damages, treble damages, and injunctive relief as permitted by law for the injuries they suffered as a result of Biogen's conspiracy to monopolize.

**CLAIM THREE**  
**VIOLATION OF 15 U.S.C. § 13(c)**  
**COMMERCIAL BRIBERY**

321. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

322. Commercial bribery violates Section 2(c) of the Robinson-Patman Act. As described in this Complaint, Biogen engaged in a commercial bribery scheme relating to the sale of fumarate drug products in the United States.

323. PBMs have, and hold themselves out as having, superior knowledge and expertise about price negotiations with brand-drug manufacturers and the use of formularies to reduce the cost of prescription drugs. Because of the PBMs' superior knowledge and expertise, health plans retain PBMs to negotiate with Biogen and other drug manufacturers on their behalf.

324. PBMs tell their health plan clients and the public that they help health plans reduce the costs associated with providing prescription drugs to plan subscribers. Health plans rely on PBMs to control decisions about formulary inclusion and placement, trusting that the

PBMs will use their skill, knowledge, and influence in the prescription drug industry to lower their clients' prescription drug costs.

325. Based on the relationship between PBMs and their health-plan clients, PBMs owe a fiduciary duty or a duty of fidelity or obligation to those clients, including to Plaintiffs and Class members.

326. When Biogen negotiates with a PBM regarding the price of Tecfidera or Vumerity, Biogen knows that the PBM is negotiating on behalf of the PBM's health-plan clients who are purchasing those drugs for their plan members.

327. Biogen knowingly made payments to the PBMs and their affiliated aggregators that were conditioned on the PBMs not advantaging lower cost generic Tecfidera over Tecfidera and Vumerity on plan formularies. Biogen made those payments so that Biogen could continue charging excessive and supracompetitive prices for Tecfidera and Vumerity by limiting competition from generic Tecfidera. Biogen knew that these rebates and fees were actually commercial bribes and that the PBMs would retain some or all of the payments for themselves and would not disclose the retained portion of the payment to their clients, the plans.

328. The PBMs kept some or all of Biogen's payments for themselves. Moreover, the PBMs did not disclose to their health-plan clients that the PBMs had received payments from Biogen in exchange for impairing competition from generic Tecfidera, or that Biogen and the PBMs were impairing that competition in the service of switching the market from Tecfidera to Vumerity.

329. By accepting and keeping Biogen's payments in exchange for impairing generic Tecfidera, the PBMs violated their fiduciary duty or duty of fidelity or obligation owed to their

health-plan clients. Impairing generic Tecfidera raised their health plan clients' costs, which was the opposite of what the health plans trusted the PBMs to do for them.

330. There is no legitimate business justification for impairing generic Tecfidera. Generic Tecfidera produces the same active ingredient as Tecfidera and Vumerity, and generic Tecfidera is substantially less costly than Tecfidera and Vumerity.

331. Biogen's payments to PBMs were conditioned on disadvantaging generic Tecfidera on the PBMs' formularies and were therefore commercial bribes in violation of Section 2(c) of the Robinson-Patman Act.

332. Had Biogen not bribed the PBMs, the PBMs would have given generic Tecfidera more favorable placement on their formularies to promote the use of generic Tecfidera over the higher-cost Tecfidera and Vumerity. Favorable placement on the PBMs' formularies for generic Tecfidera would have resulted in a significant shift in sales to the lower-cost generic Tecfidera from the higher-cost Tecfidera and Vumerity.

333. Biogen's bribery scheme has corrupted what should be legitimate negotiations between PBMs and drug manufacturers to reduce the costs associated with administering prescription drug benefits. The proper role of PBMs is to use formulary placement decisions to generate competition among manufacturers of drugs with similar applications. By awarding more favorable formulary placement to the least costly drug, PBMs create incentives for drug manufacturers to become the lowest-cost provider.

334. In contrast, Biogen made payments to the PBMs with the intent of improperly influencing or corrupting the PBMs' process of awarding favorable formulary placement to low-cost products over higher-cost alternatives. Biogen used those payments to significantly impair competition from generic Tecfidera, the lowest-cost option, while promoting the use of higher-

cost Tecfidera and Vumerity. In this scheme, Biogen and the PBMs benefitted at the expense of Plaintiffs and Class members.

335. Plaintiffs and Class members were injured by Biogen's bribery scheme because they paid supracompetitive prices for fumarate. Plaintiffs therefore have suffered substantial damages in the form of overcharges on fumarate. Plaintiffs' and the Class members' injury is the type of injury that the antitrust laws were designed to prevent and flows from the anticompetitive effects that make Biogen's acts unlawful.

336. Plaintiffs and Class members seek damages, treble damages, and injunctive relief as permitted by law for the injuries they suffered as a result of Biogen's anticompetitive conduct.

**CLAIM FOUR**  
**CONTRACTS IN RESTRAINT OF TRADE UNDER STATE LAW**

337. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

338. Biogen entered into agreements with each of the three PBMs pursuant to which it agreed to pay, and did pay, substantial kickbacks to each of them in exchange for each of their reciprocal agreement to disadvantage generic Tecfidera on their formularies and/or to designate generic Tecfidera as a specialty drug. Biogen made each of the agreements with the purpose and effect of impairing generic competition to buy time for Biogen to switch the market from Tecfidera to Vumerity. When entering into the agreements, each of the three PBMs knew and understood Biogen's intent and the agreements' likely effect.

339. The purpose and effect of Biogen's payments to the three PBMs under the agreements was to substantially impair competition from generic Tecfidera. There is and was no legitimate, non-pretextual, procompetitive business justification for the payments that outweighs

their harmful effects. Even if there were some such conceivable justification, the payments were not necessary to achieve such a purpose.

340. The agreements, individually and collectively, covered a sufficiently substantial percentage of the relevant commerce to harm competition.

341. As a direct and proximate result of Biogen's unlawful restraint of trade, Plaintiffs and Class members paid artificially inflated prices for fumarate and were harmed as a result.

342. By engaging in the foregoing conduct, Biogen has violated the following state laws:

- a. Ariz. Rev. Stat. §§ 44-1401, *et seq.*, with respect to purchase of fumarate in Arizona by class members and/or purchases by Arizona residents.
- b. Ca. Bus. & Prof. §§ 16700, 17200, *et seq.*, with respect to purchase of fumarate in California by class members and/or purchases by California residents.
- c. Conn. Gen. Stat. §§ 35-24, *et seq.*, with respect to purchase of fumarate in Connecticut by class members and/or purchases by Connecticut residents.
- d. D.C. Code Ann. §§ 28-4501, *et seq.*, with respect to purchase of fumarate in the District of Columbia by class members and/or purchases by D.C. residents.
- e. Fla. Stat. §§ 501.201, *et seq.*, with respect to purchases in Florida by members of the Class and/or purchases by Florida residents.
- f. 740 Ill. Comp. Stat. 10/1, *et seq.*, with respect to purchase of fumarate in Illinois by class members and/or purchases by Illinois residents.
- g. Iowa Code §§ 553.1, *et seq.*, with respect to purchase of fumarate in Iowa by class members and/or purchases by Iowa residents.
- h. Kan. Stat. §§ 50-101, *et seq.*, with respect to purchase of fumarate in Kansas by class members and/or purchases by Kansas residents.
- i. Mass. Ann. Laws ch. 93, *et seq.*, with respect to purchase of fumarate in Massachusetts by class members and/or purchases of Massachusetts residents.
- j. Me. Rev. Stat. 10 §§ 1102, *et seq.*, with respect to purchase of fumarate in Maine by class members and/or purchases by Maine residents.

- k. Md. Com'l Law Code Ann. §§ 11-201, *et seq.*, with respect to purchase of fumarate in Maryland by class members and/or purchases by Maryland residents.
- l. Mich. Comp. Laws §§ 445.771, *et seq.*, with respect to purchase of fumarate in Michigan by class members and/or purchases by Michigan residents.
- m. Minn. Stat. §§ 325D.49, *et seq.*, with respect to purchase of fumarate in Minnesota by class members and/or purchases by Minnesota residents.
- n. Miss. Code §§ 75-21-1, *et seq.*, with respect to purchase of fumarate in Mississippi by class members and/or purchases by Mississippi residents.
- o. Neb. Code §§ 59-801, *et seq.*, with respect to purchase of fumarate in Nebraska by class members and/or purchases by Nebraska residents.
- p. Nev. Rev. Stat. §§ 598A.010, *et seq.*, with respect to purchase of fumarate in Nevada by class members and/or purchases by Nevada residents.
- q. N.H. Rev. Stat. §§ 356:1, *et seq.*, with respect to purchase of fumarate in New Hampshire by class members and/or purchases by New Hampshire residents.
- r. N.M. Stat. §§ 57-1-1, *et seq.*, with respect to purchase of fumarate in New Mexico by class members and/or purchases by New Mexico residents.
- s. N.C. Gen. Stat. §§ 75-1, *et seq.*, with respect to purchase of fumarate in North Carolina by class members and/or purchases by North Carolina residents.
- t. N.D. Cent. Code §§ 51-08.1-01, *et seq.*, with respect to purchase of fumarate in North Dakota by class members and/or purchases by North Dakota residents.
- u. N.Y. Gen. Bus. Law § 340, *et seq.*, with respect to purchase of fumarate in New York by class members and/or purchases by New York residents.
- v. Or. Rev. Stat. §§ 646.705, *et seq.*, with respect to purchase of fumarate in Oregon by class members and/or purchases by Oregon residents.
- w. P.R. Laws tit. 10 §§ 257, *et seq.*, with respect to purchase of fumarate in Puerto Rico by class members and/or purchases by Puerto Rico residents.
- x. R.I. Gen. Laws §§ 6-36-1, *et seq.*, with respect to purchase of fumarate in Rhode Island by class members and/or purchases by Rhode Island residents.

- y. S.D. Codified Laws §§ 37-1-3.1, *et seq.*, with respect to purchase of fumarate in South Dakota by class members and/or purchases by South Dakota residents.
- z. Tenn. Code Ann. §§ 47-25-101, *et seq.*, with respect to purchases in Tennessee by members of the Class and/or by Tennessee residents.
- aa. Utah Code Ann. §§ 76-10-3101, *et seq.* with respect to purchase of fumarate in Utah by class members and/or purchases by Utah residents.
- bb. W.Va. Code §§ 47-18-1, *et seq.*, with respect to purchase of fumarate in West Virginia by class members and/or purchases by West Virginia residents.
- cc. Wis. Stat. §§ 133.01, *et seq.*, with respect to purchase of fumarate in Wisconsin by class members and/or purchases by Wisconsin residents.

343. Plaintiffs and Class members have been injured in their business or property by reason of Biogen's antitrust violations. These injuries are of the type that the laws of the above States, the District of Columbia, and Puerto Rico were designed to prevent, and flow from that which makes Biogen's conduct unlawful.

344. Plaintiffs and the Class seek damages, multiple damages, and other relief as permitted by law.

**CLAIM FIVE**  
**MONOPOLIZATION**  
**UNDER STATE LAW**

345. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

346. At all relevant times, Biogen possessed substantial market power (i.e. monopoly power) in the relevant market. Biogen possessed the power to raise and maintain supracompetitive prices and exclude competitors from the relevant market.

347. Biogen engaged in an exclusionary, anticompetitive scheme designed to create and maintain a monopoly in the market for fumarate. Biogen's anticompetitive scheme included,



cumulatively and in the alternative: (a) paying one or more of the three PBMs to disadvantage generic Tecfidera on their formularies and/or to designate generic Tecfidera as a specialty drug; and (b) switching the market from Tecfidera to Vumerity.

348. Through the anticompetitive scheme described above, Biogen willfully maintained and continues to maintain monopoly power in the relevant market using restrictive and exclusionary conduct, rather than by providing better products or services, and thereby injured the Plaintiffs and Class members.

349. Biogen's conscious objective was and is to continue its dominance of the relevant market by and through the anticompetitive scheme described above.

350. Biogen's anticompetitive scheme harmed competition and purchasers as alleged above.

351. There are no non-pretextual procompetitive justifications for Biogen's conduct. Even if there were such a conceivable justification, the conduct's anticompetitive effects far outweigh any conceivable justification. Further, the anticompetitive scheme was far broader than necessary to achieve any conceivable procompetitive benefit.

352. Biogen's anticompetitive scheme was the direct and proximate cause of the injuries to Plaintiffs and Class members.

353. Plaintiffs and the Class members have been injured in their business or property as a direct and proximate result of Biogen's anticompetitive conduct, and their injuries are the type that the statutes were designed to prevent, and flow from that which makes Biogen's conduct unlawful.

354. Plaintiffs and the Class members seek damages and treble damages as permitted by law for the injuries they suffered as a result of the Biogen's anticompetitive conduct.

355. By engaging in the foregoing conduct, Biogen has violated the following state laws:

- a. Ariz. Rev. Stat. §§ 44-1401, *et seq.*, with respect to purchase of fumarate in Arizona by class members and/or purchases by Arizona residents.
- b. Ca. Bus. & Prof. §§ 16700, 17200, *et seq.*, with respect to purchase of fumarate in California by class members and/or purchases by California residents.
- c. Conn. Gen. Stat. §§ 35-24, *et seq.*, with respect to purchase of fumarate in Connecticut by class members and/or purchases by Connecticut residents.
- d. D.C. Code Ann. §§ 28-4501, *et seq.*, with respect to purchase of fumarate in the District of Columbia by class members and/or purchases by D.C. residents.
- e. Fla. Stat. §§ 501.201, *et seq.*, with respect to purchases in Florida by members of the Class and/or purchases by Florida residents.
- f. 740 Ill. Comp. Stat. 10/1, *et seq.*, with respect to purchase of fumarate in Illinois by class members and/or purchases by Illinois residents.
- g. Iowa Code §§ 553.1, *et seq.*, with respect to purchase of fumarate in Iowa by class members and/or purchases by Iowa residents.
- h. Kan. Stat. §§ 50-101, *et seq.*, with respect to purchase of fumarate in Kansas by class members and/or purchases by Kansas residents.
- i. Mass. Ann. Laws ch. 93, *et seq.*, with respect to purchase of fumarate in Massachusetts by class members and/or purchases of Massachusetts residents.
- j. Me. Rev. Stat. 10 §§ 1102, *et seq.*, with respect to purchase of fumarate in Maine by class members and/or purchases by Maine residents.
- k. Md. Com'l Law Code Ann. §§ 11-201, *et seq.*, with respect to purchase of fumarate in Maryland by class members and/or purchases by Maryland.
- l. Mich. Comp. Laws §§ 445.771, *et seq.*, with respect to purchase of fumarate in Michigan by class members and/or purchases by Michigan residents.
- m. Minn. Stat. §§ 325D.49, *et seq.*, with respect to purchase of fumarate in Minnesota by class members and/or purchases by Minnesota residents.

- n. Miss. Code §§ 75-21-1, *et seq.*, with respect to purchase of fumarate in Mississippi by class members and/or purchases by Mississippi residents.
- o. Neb. Code §§ 59-801, *et seq.*, with respect to purchase of fumarate in Nebraska by class members and/or purchases by Nebraska residents.
- p. Nev. Rev. Stat. §§ 598A.010, *et seq.*, with respect to purchase of fumarate in Nevada by class members and/or purchases by Nevada residents.
- q. N.H. Rev. Stat. §§ 356:1, *et seq.*, with respect to purchase of fumarate in New Hampshire by class members and/or purchases by New Hampshire residents.
- r. N.M. Stat. §§ 57-1-1, *et seq.*, with respect to purchase of fumarate in New Mexico by class members and/or purchases by New Mexico residents.
- s. N.C. Gen. Stat. §§ 75-1, *et seq.*, with respect to purchase of fumarate in North Carolina by class members and/or purchases by North Carolina residents.
- t. N.D. Cent. Code §§ 51-08.1-01, *et seq.*, with respect to purchase of fumarate in North Dakota by class members and/or purchases by North Dakota residents.
- u. N.Y. Gen. Bus. Law § 340, *et seq.*, with respect to purchase of fumarate in New York by class members and/or purchases by New York residents.
- v. Or. Rev. Stat. §§ 646.705, *et seq.*, with respect to purchase of fumarate in Oregon by class members and/or purchases by Oregon residents.
- w. P.R. Laws tit. 10 §§ 257, *et seq.*, with respect to purchase of fumarate in Puerto Rico by class members and/or purchases by Puerto Rico residents.
- x. R.I. Gen. Laws §§ 6-36-1, *et seq.*, with respect to purchase of fumarate in Rhode Island by class members and/or purchases by Rhode Island residents.
- y. S.D. Codified Laws §§ 37-1-3.1, *et seq.*, with respect to purchase of fumarate in South Dakota by class members and/or purchases by South Dakota residents.
- z. Tenn. Code Ann. §§ 47-25-101, *et seq.*, with respect to purchases in Tennessee by members of the Class and/or purchases by Tennessee residents.
- aa. Utah Code Ann. §§ 76-10-3101, *et seq.* with respect to purchase of fumarate in Utah by class members and/or purchases by Utah residents.

- bb. W.Va. Code §§ 47-18-1, *et seq.*, with respect to purchase of fumarate in West Virginia by class members and/or purchases by West Virginia residents.
- cc. Wis. Stat. §§ 133.01, *et seq.*, with respect to purchase of fumarate in Wisconsin by class members and/or purchases by Wisconsin residents.

356. Plaintiffs and Class members have been injured in their business or property by reason of Biogen's antitrust violations. These injuries are of the type that the laws of the above States, the District of Columbia, and Puerto Rico were designed to prevent, and flow from that which makes Biogen's conduct unlawful.

357. Plaintiffs and the Class seek damages, multiple damages, and other relief as permitted by law.

**CLAIM SIX**  
**CONSPIRACY TO MONOPOLIZE**  
**UNDER STATE LAW**

358. Plaintiffs incorporate by reference each preceding and succeeding paragraph as though fully set forth herein.

359. At all relevant times, Biogen possessed substantial market power (i.e. monopoly power) in the relevant market. Biogen possessed the power to raise and maintain supracompetitive prices and exclude competitors from the relevant market.

360. Biogen conspired with the PBMs and their specialty pharmacies to create and maintain a monopoly in the market for fumarate. Biogen's and the PBMs and specialty pharmacies' engaged in anticompetitive conduct in furtherance of its conspiracy to maintain a monopoly, which included, cumulatively and in the alternative: (a) agreeing to pay and paying one or more of the three PBMs to disadvantage generic Tecfidera on their formularies and/or to designate generic Tecfidera as a specialty drug; (b) conspiring to switch the market from Tecfidera to Vumerity; and (c) entering into agreements that caused Plaintiffs and Class

members to be required to purchase Tecfidera, Vumerity and generic Tecfidera from the PBM-owned specialty pharmacies at supracompetitive prices; and (f) conspiring to impair generic competition and suppress sales of lower cost generic Tecfidera.

361. Through Biogen's conspiracy to monopolize, Biogen willfully maintained and continues to maintain monopoly power in the relevant market using restrictive and exclusionary conduct, rather than by providing better products or services, and thereby injured the Plaintiffs and Class members.

362. The goal, purpose and effect of the Biogen-directed conspiracy was and is to maintain and extend Biogen's monopoly over the relevant market by and through the anticompetitive conduct described above.

363. Biogen's conspiracy to monopolize harmed competition and purchasers as alleged above.

364. There are no non-pretextual procompetitive justifications for Biogen's conspiracy to monopolize. Even if there were such a conceivable justification, the conspiracy's anticompetitive effects far outweigh any conceivable justification. Further, the anticompetitive scheme was far broader than necessary to achieve any conceivable procompetitive benefit.

365. Biogen's conspiracy to monopolize was the direct and proximate cause of the injuries to Plaintiffs and Class members.

366. Plaintiffs and the Class members have been injured in their business or property as a direct and proximate result of Biogen's conspiracy to monopolize, and their injuries are the type that the statutes were designed to prevent, and flow from that which makes Biogen's conduct unlawful.

367. By engaging in the foregoing conduct, Biogen has intentionally and wrongfully conspired to monopolize in violation of the state laws alleged herein.

368. Plaintiffs and the Class members seek damages and treble damages as permitted by law for the injuries they suffered as a result of the Biogen's conspiracy to monopolize.

369. By engaging in the foregoing conduct, Biogen has violated the following state laws:

- a. Ariz. Rev. Stat. §§ 44-1401, *et seq.*, with respect to purchase of fumarate in Arizona by class members and/or purchases by Arizona residents.
- b. Ca. Bus. & Prof. §§ 16700, 17200, *et seq.*, with respect to purchase of fumarate in California by class members and/or purchases by California residents.
- c. Conn. Gen. Stat. §§ 35-24, *et seq.*, with respect to purchase of fumarate in Connecticut by class members and/or purchases by Connecticut residents.
- d. D.C. Code Ann. §§ 28-4501, *et seq.*, with respect to purchase of fumarate in the District of Columbia by class members and/or purchases by D.C. residents.
- e. Fla. Stat. §§ 501.201, *et seq.*, with respect to purchases in Florida by members of the Class and/or purchases by Florida residents.
- f. 740 Ill. Comp. Stat. 10/1, *et seq.*, with respect to purchase of fumarate in Illinois by class members and/or purchases by Illinois residents.
- g. Iowa Code §§ 553.1, *et seq.*, with respect to purchase of fumarate in Iowa by class members and/or purchases by Iowa residents.
- h. Kan. Stat. §§ 50-101, *et seq.*, with respect to purchase of fumarate in Kansas by class members and/or purchases by Kansas residents.
- i. Mass. Ann. Laws ch. 93, *et seq.*, with respect to purchase of fumarate in Massachusetts by class members and/or purchases of Massachusetts residents.
- j. Me. Rev. Stat. 10 §§ 1102, *et seq.*, with respect to purchase of fumarate in Maine by class members and/or purchases by Maine residents.
- k. Md. Com'l Law Code Ann. §§ 11-201, *et seq.*, with respect to purchase of fumarate in Maryland by class members and/or purchases by Maryland.

- l. Mich. Comp. Laws §§ 445.771, *et seq.*, with respect to purchase of fumarate in Michigan by class members and/or purchases by Michigan residents.
- m. Minn. Stat. §§ 325D.49, *et seq.*, with respect to purchase of fumarate in Minnesota by class members and/or purchases by Minnesota residents.
- n. Miss. Code §§ 75-21-1, *et seq.*, with respect to purchase of fumarate in Mississippi by class members and/or purchases by Mississippi residents.
- o. Neb. Code §§ 59-801, *et seq.*, with respect to purchase of fumarate in Nebraska by class members and/or purchases by Nebraska residents.
- p. Nev. Rev. Stat. §§ 598A.010, *et seq.*, with respect to purchase of fumarate in Nevada by class members and/or purchases by Nevada residents.
- q. N.H. Rev. Stat. §§ 356:1, *et seq.*, with respect to purchase of fumarate in New Hampshire by class members and/or purchases by New Hampshire residents.
- r. N.M. Stat. §§ 57-1-1, *et seq.*, with respect to purchase of fumarate in New Mexico by class members and/or purchases by New Mexico residents.
- s. N.C. Gen. Stat. §§ 75-1, *et seq.*, with respect to purchase of fumarate in North Carolina by class members and/or purchases by North Carolina residents.
- t. N.D. Cent. Code §§ 51-08.1-01, *et seq.*, with respect to purchase of fumarate in North Dakota by class members and/or purchases by North Dakota residents.
- u. N.Y. Gen. Bus. Law § 340, *et seq.*, with respect to purchase of fumarate in New York by class members and/or purchases by New York residents.
- v. Or. Rev. Stat. §§ 646.705, *et seq.*, with respect to purchase of fumarate in Oregon by class members and/or purchases by Oregon residents.
- w. P.R. Laws tit. 10 §§ 257, *et seq.*, with respect to purchase of fumarate in Puerto Rico by class members and/or purchases by Puerto Rico residents.
- x. R.I. Gen. Laws §§ 6-36-1, *et seq.*, with respect to purchase of fumarate in Rhode Island by class members and/or purchases by Rhode Island residents.
- y. S.D. Codified Laws §§ 37-1-3.1, *et seq.*, with respect to purchase of fumarate in South Dakota by class members and/or purchases by South Dakota residents.

- z. Tenn. Code Ann. §§ 47-25-101, *et seq.*, with respect to purchases in Tennessee by members of the Class and/or purchases by Tennessee residents.
- aa. Utah Code Ann. §§ 76-10-3101, *et seq.* with respect to purchase of fumarate in Utah by class members and/or purchases by Utah residents.
- bb. W.Va. Code §§ 47-18-1, *et seq.*, with respect to purchase of fumarate in West Virginia by class members and/or purchases by West Virginia residents.
- cc. Wis. Stat. §§ 133.01, *et seq.*, with respect to purchase of fumarate in Wisconsin by class members and/or purchases by Wisconsin residents.

370. Plaintiffs and Class members have been injured in their business or property by reason of Biogen's antitrust violations. These injuries are of the type that the laws of the above States, the District of Columbia, and Puerto Rico were designed to prevent, and flow from that which makes Biogen's conduct unlawful.

371. Plaintiffs and the Class seek damages, multiple damages, and other relief as permitted by law.

## **XIX. DEMAND FOR JUDGMENT**

372. WHEREFORE, Plaintiffs, on behalf of themselves and the Class, demand judgment in their favor and respectfully requests that the Court:

- a. Determine that this action may be maintained as a class action pursuant to Fed. R. Civ. P. 23(a), 23 (b)(2) and (b)(3), and direct that reasonable notice of this action, as provided by Fed. R. Civ. P. 23(c)(2), be given to the Class and declare the Plaintiffs as representatives of the Class;
- b. Declare that the conduct alleged herein is in violation of Sections 1 and 2 of the Sherman Act, of Section 2(c) of the Robinson-Patman Act, and of the other statutes set forth above;
- c. Enter judgment against Biogen in favor of Plaintiffs and the Class;
- d. Grant Plaintiffs and the Class equitable relief in the nature of disgorgement, restitution, the creation of a constructive trust, mandatory licenses, and other injunctive relief, to remedy Biogen's anticompetitive conduct;



- e. Award the Class damages and, where applicable, treble, multiple, punitive, and/or other damages, in an amount to be determined at trial, including interest;
- f. Award Plaintiffs and the Class their costs of suit, including reasonable attorneys' fees as provided by law; and
- g. Grant such other further relief as is necessary to correct for the anticompetitive market effects caused by Biogen's unlawful conduct, and as the Court deems just.

## **XX. JURY DEMAND**

Pursuant to Federal Rule of Civil Procedure 38, Plaintiffs on behalf of themselves and the proposed Class demand a trial by jury on all issues so triable.

Dated: November 1, 2024

By: /s/ Joseph M. Vanek  
Joseph M. Vanek  
Paul E. Slater  
John P. Bjork  
SPERLING & SLATER, LLC  
55 West Monroe Street, Suite 3200  
Chicago, Illinois 60603  
Tel: (312) 641-3200  
Email: jvanek@sperling-law.com  
pes@sperling-law.com  
jbjork@sperling-law.com

Phillip F. Cramer  
Dean J. Balaes  
SPERLING & SLATER, LLC  
1221 Broadway, Suite 2140  
Nashville, TN 37212  
Tel: (312) 641-3200  
Fax: (312) 641-6492  
Email: pcramer@sperling-law.com  
dbalaes@sperling-law.com

James Almon  
SPERLING & SLATER, LLC  
2707 Killarney Way, Suite 202  
Tallahassee, FL 32309  
Tel: (850) 354-5300  
Fax: (312) 641-6492  
Email: jalmon@sperling-law.com

Ryan T. Holt (TN BPR # 30191)  
SHERRARD ROE VOIGT & HARBISON, PLC  
1600 West End Ave., Suite 1750  
Nashville, Tennessee 37203  
Tel: (615) 742-4200  
E-mail: rholt@srvhlaw.com

Steve D. Shadowen  
Nicholas W. Shadowen  
Kathryn B. Allen  
HILLIARD SHADOWEN LLP  
1717 W. 6th St., Ste. 290  
Austin, Texas 78703  
steve@hilliardshadowenlaw.com

nshadowen@hilliardshadowelaw.com  
kallen@hilliardshadowenlaw.com

*Counsel for Plaintiff Local No. 1 Health, Teamsters  
Local 237 Welfare Fund and Teamsters Local 237  
Retirees' Benefit Fund and the Putative Class*

Lee Albert  
Brian D. Brooks  
GLANCY PRONGAY & MURRAY LLP  
230 Park Ave., Suite 358  
New York, NY 10169  
Tel.: (212) 682-5340  
lalbert@glancylaw.com  
bbrooks@glancylaw.com

*Counsel for Plaintiffs Teamsters Local 237 Welfare  
Fund and Teamsters Local 237 Retirees' Benefit  
Fund and the Putative Class*

Carol V. Gilden  
ARDC No. 6185530  
COHEN MILSTEIN SELLERS & TOLL PLLC  
190 South LaSalle Street  
Suite 1705  
Chicago, IL 60603  
Tel: (312) 357-0370  
Email: cgilden@cohenmilstein.com

Sharon K. Robertson  
COHEN MILSTEIN SELLERS & TOLL PLLC  
88 Pine Street, 14th Floor  
New York, NY 10005  
Tel: (212) 838-7797  
Email: srobertson@cohenmilstein.com

*Counsel for Plaintiff, the Mayor and City Council of  
Baltimore, and the Proposed Class*

Kenneth A. Wexler  
Justin N. Boley  
Tyler J. Story  
WEXLER BOLEY & ELGERSMA LLP  
311 S. Wacker Dr., Suite 5450  
Chicago, Illinois 60606

Tel: (312) 346-222  
Email: kaw@wbe-llp.com  
jnb@wbe-llp  
tjs@wbe-llp.com

Arthur Bailey  
Rupp Pfalzgraf LLC  
111 West 2nd St., Suite 1100  
Jamestown, New York  
Tel: (716) 664-2967  
bailey@rupppfalzgraf.com

*Attorneys for Plaintiff New York State Teamsters  
Council Health and Hospital Fund and the Putative  
Class*

Gregory S. Asciolla (*pro hac vice* pending)  
Geraldyn J. Trujillo (*pro hac vice* pending)  
Alexander E. Barnett (*pro hac vice* pending)  
Jonathan S. Crevier (*pro hac vice* pending)  
DICELLO LEVITT LLP  
485 Lexington Avenue, Suite 1001  
New York, NY 10017  
Tel: (646) 933-1000  
gasciolla@dicellolevitt.com  
gtrujillo@dicellolevitt.com  
abarnett@dicellolevitt.com  
jcrevier@dicellolevitt.com

*Attorneys for Plaintiff UFCW Local 1500 Welfare  
Fund and the Putative Class*

### **CERTIFICATE OF SERVICE**

I certify that on **November 1, 2024**, I caused a true and correct copy of Plaintiffs' Consolidated Amended Class Action Complaint to be served on all counsel of record via the Court's CM/ECF system.

/s/ Joseph M. Vanek  
Joseph M. Vanek